Hyperkalemic periodic paralysis is an autosomal dominant channelopathy caused by mutations in skeletal muscle sodium channels, resulting in episodic attacks of muscle weakness associated with elevated serum potassium levels.

Exam domain	One-glance essentials
Definition / diagnosis	Autosomal-dominant SCN4A skeletal-muscle sodium-channelopathy causing episodic flaccid weakness ^[1]^[2] Serum K⁺ is often mildly high during attacks and normal between attacks ^[2]^[3]
Epidemiology / risks	Usually begins in childhood with high penetrance and equal sex distribution ^[1]^[2] Exercise/rest, fasting, cold, K⁺-rich food and anaesthesia can precipitate attacks ^[2]
Core mechanism	Impaired Nav1.4 inactivation → persistent Na⁺ current → depolarisation ^[2] Mild depolarisation causes myotonia; sustained depolarisation causes inexcitability and paralysis ^[2]
Clinical picture	Brief attacks of proximal > distal, legs > arms flaccid weakness, usually minutes to hours ^[1]^[2] Myotonia between/early in attacks separates it from HypoPP and TPP ^[1]^[2] Sensation is intact; respiratory/bulbar muscles are usually spared ^[2]
Investigations	During attack: repeat non-haemolysed K⁺, ECG, renal/adrenal assessment and TFT ^[3]^[4] EMG may show myotonic discharges; long-exercise testing supports channelopathy ^[2] Confirm with SCN4A genetic testing ^[2]
Management	Cardiac monitoring; carbohydrate, mild exercise or inhaled β₂-agonist may abort mild attacks ^[2] Treat severe hyperkalaemic ECG toxicity conventionally: IV calcium stabilises myocardium but does not lower K⁺ ^[4] Prevention: trigger/low-K⁺ diet ± thiazide or carbonic-anhydrase inhibitor ^[2]
Complications	Arrhythmia is uncommon with mild K⁺ rise but requires ECG monitoring ^[4] Recurrent attacks may lead to fixed proximal myopathy in later life ^[2] Falls, anaesthetic crises and rare rhabdomyolysis ^[2]
Prevention / follow-up	Avoid fasting, cold, strenuous exercise and K⁺ loads; use an individual attack plan ^[2] Genetic counselling: AD inheritance gives a 50% transmission risk ^[2] Perioperative normothermia, glucose/K⁺ monitoring and anaesthetic planning ^[2]
Exam traps	Exclude pseudohyperkalaemia before attributing weakness to K⁺ ^[3]^[4] Do not give potassium: management is the opposite of HypoPP/TPP ^[2] Avoid succinylcholine, which can worsen hyperkalaemia/depolarisation ^[2]

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 1652, Periodic Paralysis) ^[2] Senior notes: Ryan Ho Neurology.pdf (pp. 191–194, Channelopathies and Periodic Paralysis) ^[3] Lecture slides: Chemical Pathology Seminar_Potassium.pdf (pp. 32–33) ^[4] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (pp. 27, 29)

Hyperkalemic Periodic Paralysis (HyperKPP)

Hyperkalemic Periodic Paralysis (HyperKPP) is a rare inherited skeletal-muscle channelopathy characterised by episodic attacks of flaccid muscle weakness accompanied by elevated or high-normal serum potassium levels. The name itself is instructive:

"Hyper-kalemic" → "hyper" = excess, "kal-" from Latin kalium (potassium), "-emic" = in the blood → excess potassium in the blood
"Periodic" → attacks recur at intervals, not continuously present
"Paralysis" → loss of voluntary muscle function during attacks

It belongs to the family of periodic paralyses, which are muscle disorders classified under channelopathies — diseases caused by dysfunction of ion channels in skeletal muscle membranes ^[1]^[2]. The fundamental problem is a gain-of-function mutation in the voltage-gated sodium channel (Nav1.4) of skeletal muscle, encoded by the SCN4A gene, leading to aberrant membrane depolarisation and muscle inexcitability during attacks ^[1]^[2].

"Periodic paralysis is a muscle disorder in the family of disease called channelopathies manifested by episodes of painless muscle weakness" ^[1]

Key Distinction

HyperKPP is fundamentally different from secondary hyperkalemia causing weakness (e.g., renal failure, ACEi use). In HyperKPP, the total body potassium is normal — the problem is an abnormal release of potassium from muscle cells due to a leaky sodium channel, and the muscle membrane itself is intrinsically abnormal, making it vulnerable to even mild elevations in extracellular [K⁺].

Feature	Detail
Prevalence	Rare (~1 in 200,000) ^[2]
Inheritance	Autosomal dominant (AD) with near-complete penetrance ^[1]^[3]
Sex distribution	Males and females are equally affected (contrast with hypoKPP and TPP which are male-predominant) ^[1]
Age of onset	1–10 years old (earliest onset among the periodic paralyses; hypoKPP starts at 10–20 years, TPP at > 20 years) ^[1]
Ethnic predilection	No particular ethnic predominance (unlike TPP which is vastly more common in Asians)
Natural history	Attack frequency and severity tend to decrease after the 4th–5th decade, but patients may develop a fixed progressive proximal myopathy (permanent weakness) from the 4th to 6th decades ^[2]

"Near complete penetrance" — meaning almost all individuals who carry the mutation will manifest clinical disease, unlike hypokalemic PP where "non-penetrance is common especially in females" ^[1].

High Yield Comparison Table from Felix Lai Notes

Remember the age-of-onset pattern for exams: HyperKPP (1–10 y) → HypoKPP (10–20 y) → TPP ( > 20 y). The earlier the onset, the more likely it is a primary genetic channelopathy. TPP is acquired (secondary to thyrotoxicosis) and therefore presents later.

3. Anatomy and Function of the Relevant Ion Channel

The skeletal muscle voltage-gated sodium channel Nav1.4 is the key structure affected in HyperKPP.

Gene: SCN4A (Sodium Channel, voltage-gated, type IV, alpha subunit) — located on chromosome 17q23.3
Protein: Nav1.4 — the alpha subunit of the sodium channel expressed exclusively in skeletal muscle
Structure: The alpha subunit consists of 4 homologous domains (DI–DIV), each containing 6 transmembrane segments (S1–S6). The S4 segments are the voltage sensors (positively charged arginine/lysine residues that move in response to membrane depolarisation). The loop between S5 and S6 forms the ion-selective pore.
Function: When the membrane depolarises (e.g., at the neuromuscular junction after acetylcholine binds nicotinic receptors), the Nav1.4 channel opens transiently, allowing Na⁺ influx → generates the action potential → propagates along the sarcolemma → T-tubule depolarisation → excitation-contraction coupling → muscle contraction.
Inactivation: Critically, the channel has a fast inactivation gate (the "h gate" or inactivation particle, formed by the intracellular loop between DIII and DIV). After opening, the channel rapidly inactivates within 1–2 ms, ensuring the action potential is brief and the membrane can repolarise. This is essential for the refractory period and normal repetitive firing.

Skeletal muscle is the largest reservoir of potassium in the body (~98% of total body K⁺ is intracellular, mostly in muscle).
The resting membrane potential of skeletal muscle (~−90 mV) is predominantly set by the K⁺ equilibrium potential (Nernst equation), determined by the ratio of intracellular to extracellular [K⁺].
Even small changes in extracellular [K⁺] can shift the resting membrane potential significantly:
- Hyperkalemia → decreased [K⁺]in/[K⁺]out ratio → depolarisation of the resting membrane potential (makes it less negative).
- Mild depolarisation may initially make the muscle more excitable (myotonia), but sustained depolarisation inactivates sodium channels → muscle becomes inexcitable → weakness/paralysis.
The Na⁺/K⁺-ATPase pump maintains the gradient (3 Na⁺ out, 2 K⁺ in), and is regulated by insulin, catecholamines (β₂-adrenergic), thyroid hormones, and aldosterone.

In HyperKPP, mutations in Nav1.4 impair fast inactivation. This means:

When the membrane is mildly depolarised (e.g., by a small rise in extracellular K⁺), mutant channels fail to inactivate properly → persistent inward Na⁺ current.
This persistent Na⁺ current further depolarises the membrane.
At a critical level of depolarisation (~−50 to −60 mV), even the normal sodium channels become inactivated (they cannot be recruited for action potentials).
The muscle fibre enters a state of depolarisation block — no action potentials can be generated → flaccid weakness/paralysis.
The sustained depolarisation also opens K⁺ channels and drives K⁺ out of the cell → hyperkalemia (the hyperkalemia is a consequence of the attack, not just the cause).

4. Etiology

HyperKPP is caused by gain-of-function mutations in the SCN4A gene (autosomal dominant) ^[1]^[2]^[3].

Mutation	Location	Frequency	Clinical Notes
T704M (Thr→Met)	Domain II, S5 segment	~50% of cases	Most common; associated with more severe attacks and myotonia
M1592V (Met→Val)	Domain IV, S6 segment	~30% of cases	Second most common; milder phenotype, less myotonia
Other (e.g., I693T, A1156T)	Various	~20%	Variable severity

All these mutations affect the inactivation kinetics of the sodium channel, allowing a small "leak" or persistent current when the channel should be closed.
The inheritance is autosomal dominant — a single mutant allele is sufficient because the abnormal channels dominate the membrane behaviour (dominant-negative or gain-of-function mechanism) ^[1]^[3].

"Precipitated by exercise, cold, hyperK" ^[3]

"Triggers include exercise, fasting, cold exposure, anaesthesia, ingestion of K salts" ^[2]

Understanding the triggers requires understanding why they worsen the channel defect:

Trigger	Mechanism
Rest after exercise	During exercise, catecholamines stimulate Na⁺/K⁺-ATPase → K⁺ driven into cells. After exercise stops, the pump activity decreases, and K⁺ leaks back out → transient rise in extracellular [K⁺] → depolarises membrane → triggers attack via mutant channels
Fasting	Low insulin state → reduced K⁺ uptake into cells → mild rise in extracellular [K⁺]; also, fasting-induced release of fatty acids may directly affect channel gating
Cold exposure	Cold slows Na⁺/K⁺-ATPase pump activity (enzyme kinetics) → reduced K⁺ uptake → mild hyperkalemia; cold also directly slows channel inactivation kinetics
K⁺-rich meals	Direct increase in extracellular [K⁺] → membrane depolarisation → triggers attack
Anaesthesia	Certain anaesthetic agents (especially succinylcholine, a depolarising neuromuscular blocker) can trigger massive K⁺ release from muscle; halogenated agents can also affect channel function (overlap with malignant hyperthermia susceptibility in some SCN4A mutations)
Stress	Catecholamine surge → initial K⁺ shift into cells (β₂ effect), but during the "recovery" phase, K⁺ re-equilibrates outward → transient hyperkalemia

Critical Contrast: HyperKPP vs HypoKPP/TPP Triggers

Students commonly confuse triggers. In HyperKPP, attacks are triggered by fasting, K⁺-rich meals, and cold — things that raise extracellular K⁺. In HypoKPP/TPP, attacks are triggered by high-carbohydrate meals, insulin, and β₂-agonists — things that shift K⁺ INTO cells. The triggers are essentially opposite because the underlying channel defects are different (Na⁺ channel in HyperKPP vs Ca²⁺ channel in most HypoKPP).

5. Pathophysiology

Step-by-step explanation:

Baseline: The patient's skeletal muscle expresses both normal (wild-type) and mutant Nav1.4 channels (heterozygous, AD inheritance).
At rest (between attacks): The mutant channels function nearly normally, so the patient has normal or near-normal strength. However, there may be subclinical myotonia (see below).
Trigger occurs (e.g., fasting raises extracellular [K⁺] slightly, from 4.0 → 5.0 mmol/L):
- This mild rise in extracellular K⁺ depolarises the resting membrane potential from −90 mV to −80 mV.
- In a normal person, this small shift is tolerated — the sodium channels can still inactivate properly.
- In HyperKPP, the mutant channels fail to fully inactivate at this membrane potential → a persistent Na⁺ current flows inward.
Persistent Na⁺ current → further depolarisation → more K⁺ efflux (through voltage-gated K⁺ channels and "leak" channels) → extracellular [K⁺] rises further.
Positive feedback loop: Rising extracellular [K⁺] → more depolarisation → more persistent Na⁺ current → more K⁺ efflux → escalating depolarisation.
Depolarisation block: When the membrane potential reaches ~−50 to −60 mV, all sodium channels (both normal and mutant) are in the inactivated state → no action potentials can be generated → flaccid paralysis.
Resolution: Over time (minutes to hours), the Na⁺/K⁺-ATPase gradually restores the K⁺ gradient, the membrane repolarises, sodium channels recover from inactivation, and strength returns.

"May develop myotonia between attacks" ^[2]
At mildly elevated extracellular [K⁺] (before full depolarisation block), the persistent Na⁺ current through mutant channels makes the membrane hyperexcitable — it fires repetitive action potentials spontaneously → myotonia (sustained involuntary muscle contraction, clinically perceived as muscle stiffness).
As extracellular [K⁺] rises further, the membrane becomes too depolarised for any action potentials → myotonia gives way to weakness (the "paradoxical" transition from stiffness to weakness).
This sequence — myotonia → weakness — is characteristic of HyperKPP and helps distinguish it from HypoKPP (where myotonia is NOT a feature).

Repeated episodes of sustained depolarisation cause calcium overload in muscle fibres (via voltage-gated Ca²⁺ channels that open during depolarisation and via reverse-mode Na⁺/Ca²⁺ exchange).
Chronic calcium overload activates calpains (calcium-dependent proteases) → progressive myofibre damage → vacuolar myopathy → permanent proximal weakness.
This typically manifests from the 4th to 6th decades and is a major source of long-term disability.

6. Classification

Key comparison table (from Felix Lai Notes ^[1]):

Feature	Thyrotoxic PP (TPP)	Hypokalemic PP (HypoKPP)	Hyperkalemic PP (HyperKPP)
Type	Acquired (2° to thyrotoxicosis)	Inherited (AD)	Inherited (AD)
Gene	Susceptibility locus 17q24.3 (HKU discovery)	CACNA1S (70%) or SCN4A	SCN4A
Channel	Na⁺/K⁺-ATPase hyperactivity	Ca²⁺ channel (DHP receptor) or Na⁺ channel	Na⁺ channel (Nav1.4)
Serum K⁺ during attack	Low (mean ~2.1 mmol/L)	Low	High or high-normal
Age of onset	> 20 years (20–39)	10–20 years	1–10 years
Sex	Male predominant (60:1)	Male predominant	Males and females equally affected
Penetrance	N/A	Non-penetrance common (esp. females)	Near-complete penetrance
Myotonia	Absent	Absent	Present (between/early in attacks)
Attack duration	Hours to days	6–24 hours	Spontaneously resolved over a few hours (shorter)
Precipitants	High-CHO meals, exercise, stress	High-CHO meals, exercise, stress	Exercise, fasting, cold, K⁺-rich meals
Associated features	Signs of thyrotoxicosis	None	Myotonia, late progressive myopathy

Based on the degree of myotonia, HyperKPP can be further subdivided (though this is more academic than exam-relevant):

HyperKPP with myotonia (most common, typically T704M mutation): Clear clinical and EMG myotonia between attacks.
HyperKPP without myotonia (some M1592V mutations): Weakness attacks without clinical myotonia, though EMG may still show myotonic discharges.
Overlap with Paramyotonia Congenita (PMC): Some SCN4A mutations cause features of both HyperKPP and PMC (paradoxical myotonia — myotonia that worsens with repeated movement, especially in cold). This is because PMC is also an SCN4A channelopathy, just with different mutations affecting different aspects of channel inactivation.

SCN4A mutations cause a spectrum of diseases:

HyperKPP (impaired fast inactivation → periodic paralysis + myotonia)
Paramyotonia Congenita (cold-induced myotonia + weakness)
Sodium Channel Myotonia (myotonia without periodic paralysis)
HypoKPP type 2 (some SCN4A mutations cause hypokalemic, not hyperkalemic, attacks — these involve the S4 voltage-sensor mutations creating anomalous "gating pore" currents)

This spectrum reinforces that the clinical phenotype depends on which part of the channel is mutated and how it alters channel gating.

7. Clinical Features

7.1 Symptoms

Description: Attacks of painless flaccid weakness ranging from mild focal weakness (e.g., one limb) to generalised paralysis ^[2].
"Attacks of focal or generalised weakness with hypotonia" ^[2]
"Spontaneously resolved over a few hours" ^[3]
Distribution: Proximal > distal, lower limbs > upper limbs (similar to all periodic paralyses — large proximal muscles have greater metabolic demands and more Na⁺/K⁺-ATPase turnover) ^[2].
"Usually spares respiratory and bulbar muscles" ^[2] — because these muscles have different channel expression profiles and are under continuous neural drive (which helps maintain membrane polarisation).
Duration: Usually minutes to a few hours (shorter than HypoKPP attacks which last 6–24 hours) ^[1]^[3]. This is because the hyperkalemia is transient and the Na⁺/K⁺-ATPase can correct the extracellular [K⁺] relatively quickly.
Frequency: Variable — can be daily, weekly, or monthly. Attack frequency tends to decrease with age but may be replaced by fixed myopathy.
Onset: Characteristically in the first decade of life (1–10 years old) ^[1].
Pathophysiology: As explained above — mutant Nav1.4 channels fail to inactivate during mild hyperkalemia → persistent Na⁺ current → depolarisation block → inexcitable muscle membrane.

Description: Involuntary sustained muscle contraction, experienced as "stiffness" or difficulty relaxing a grip. The patient may say "I can't let go after shaking someone's hand."
"May develop myotonia between attacks" ^[2]
Myotonia can occur between attacks (interictal myotonia) or at the onset of an attack (before weakness supervenes).
Distribution: Most prominent in the hands, eyelids (lid lag on attempted downgaze), and facial muscles.
Pathophysiology: At mildly elevated extracellular [K⁺], the persistent Na⁺ current through mutant channels → membrane hyperexcitability → repetitive firing → myotonia. This is the pre-paralytic phase.
Clinical significance: Myotonia is a distinguishing feature of HyperKPP that is NOT seen in HypoKPP or TPP. Its presence between attacks can be a diagnostic clue even when the patient is not having an attack of weakness.

"May develop proximal myopathy after attacks subside in 4th to 6th decades" ^[2]
Over decades, cumulative muscle fibre damage from repeated depolarisation → permanent proximal myopathy (vacuolar myopathy on biopsy).
This can become the predominant clinical problem in older patients, even as episodic attacks become less frequent.

Patients often identify triggers:

Weakness after rest following vigorous exercise (e.g., "I play football and then I can't get up from the bench")
Weakness in cold weather or after cold exposure
Weakness after eating potassium-rich foods (bananas, oranges, potatoes)
Weakness after fasting or missing meals

7.2 Signs

Sign	Pathophysiological Basis
Flaccid weakness (hypotonia)	Depolarisation block → no action potentials → no muscle contraction → flaccid (not spastic, because the problem is at the muscle level, not upper motor neuron)
Hyporeflexia or areflexia	Deep tendon reflexes require an intact muscle contraction response to the stretch reflex arc. If the muscle cannot generate action potentials (depolarisation block), the reflex arc is broken at the effector end → absent reflexes
Proximal > distal weakness	Proximal muscles have higher metabolic turnover and more Na⁺/K⁺-ATPase activity → more susceptible to K⁺ shifts
Lower limbs > upper limbs	LL muscles are larger → greater K⁺ flux → more vulnerable
Respiratory and bulbar muscles spared	Different channel expression profile; continuous neural drive maintains polarisation
Sensation intact	Sensory neurons use different sodium channel isoforms (Nav1.7, Nav1.8, Nav1.9) — Nav1.4 is exclusively in skeletal muscle
No cranial nerve involvement	Extraocular muscles and other cranial nerve-innervated muscles use different channel compositions

Important Differential Sign

Reflexes in HyperKPP are hypo/areflexic during attacks — this contrasts with upper motor neuron lesions (hyperreflexia) and Guillain-Barré syndrome (areflexia with ascending weakness and potentially respiratory involvement). The key distinction from GBS is: HyperKPP has no sensory involvement, no respiratory involvement, attacks resolve in hours, and there is often a family history + myotonia between attacks.

Sign	Pathophysiological Basis
Clinical myotonia	Percussion myotonia (tap thenar eminence → sustained contraction and slow relaxation), grip myotonia (difficulty releasing handshake) — due to persistent Na⁺ current causing membrane hyperexcitability at baseline
Normal strength (early in disease)	Between attacks, the membrane potential is normal → channels function normally
Lid lag	Myotonia of the levator palpebrae superioris → eyelid lags behind the globe on downgaze
Progressive proximal weakness (late disease)	Cumulative myofibre damage from repeated attacks → vacuolar myopathy
Muscle hypertrophy (some patients)	Chronic myotonia can cause compensatory hypertrophy, especially in calf muscles (similar to myotonia congenita)

Serum K⁺ during attacks is typically only mildly elevated (5.0–6.0 mmol/L), so life-threatening cardiac arrhythmias are uncommon in HyperKPP (unlike secondary hyperkalemia from renal failure where K⁺ can be > 7.0 mmol/L).
However, ECG monitoring is still warranted during attacks because:
- Some patients can have K⁺ > 6.0 mmol/L
- Even mild hyperkalemia can cause ECG changes (peaked T waves, PR prolongation)
- Rarely, cardiac arrhythmias have been reported

ECG changes of hyperkalemia (for reference): "Peaked T, widening of QRS, loss of P, sine wave, asystole" ^[4]. These progress with rising K⁺ levels but are rarely seen in HyperKPP because the hyperkalemia is typically mild and transient.

8. Important Pathophysiological Comparisons

This is a critical comparison because both may present with episodic weakness:

Feature	HyperKPP	TPP
K⁺ during attack	High	Low (mean ~2.1 mmol/L)
Mechanism	Mutant Na⁺ channel → K⁺ leak out	Thyroid hormone ↑Na⁺/K⁺-ATPase → K⁺ shift IN
Total body K⁺	Normal	Normal (transcellular shift)
Myotonia	Present	Absent
Thyroid function	Normal	Thyrotoxic (essential for pathogenesis)
Rebound K⁺ issue	Not typical	Rebound hyperkalemia after K⁺ replacement (40–59%) because total body K⁺ is actually normal or high ^[5]
Family history	AD inheritance	Usually no FHx of periodic paralysis
Demographics	Equal sex, onset 1–10 y	Asian male, onset 20–39 y

Feature	HyperKPP	HypoKPP
K⁺ during attack	High	Low
Channel	Na⁺ (SCN4A)	Ca²⁺ (CACNA1S, 70%) or Na⁺ (SCN4A, 10%)
Myotonia	Yes	No
Attack duration	Minutes to hours	6–24 hours
Precipitants	Fasting, cold, K⁺ load	CHO load, exercise, stress
Age of onset	1–10 y	10–20 y
Sex	Equal	Male predominant
Penetrance	Near-complete	Variable (incomplete in females)

High Yield Summary

Hyperkalemic Periodic Paralysis (HyperKPP) — Key Points:

Autosomal dominant channelopathy caused by SCN4A mutations (gain-of-function in skeletal muscle Na⁺ channel Nav1.4) ^[1]^[2]^[3]
Rare (~1/200,000), equal sex distribution, onset age 1–10 years, near-complete penetrance ^[1]^[2]
Precipitated by exercise, cold, fasting, K⁺-rich meals, anaesthesia ^[2]^[3]
Pathophysiology: impaired fast inactivation → persistent Na⁺ current → depolarisation block → flaccid paralysis + K⁺ efflux → mild hyperkalemia (5–6 mmol/L)
Clinical features: Episodic flaccid weakness (proximal > distal, LL > UL), spares respiratory/bulbar muscles, attacks last minutes to a few hours ^[1]^[2]^[3]
Myotonia between/early in attacks — a distinguishing feature from HypoKPP and TPP ^[2]
Late progressive proximal myopathy develops in 4th–6th decades ^[2]
Sensation intact, reflexes reduced during attacks, normal between attacks (early disease)
Cardiac arrhythmias are uncommon (mild hyperkalemia) but ECG monitoring is still warranted

Active Recall - Hyperkalemic Periodic Paralysis (Overview, Pathophysiology & Clinical Features)

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Periodic Paralysis comparison table ^[2] Senior notes: Ryan Ho Neurology.pdf — Periodic paralysis section (p. 194) ^[3] Lecture slides: Chemical Pathology Seminar_Potassium.pdf (p. 32–33) ^[4] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (p. 29) — Hyperkalemia ECG changes ^[5] Senior notes: Ryan Ho Endocrine.pdf (p. 29) — TPP section (rebound hyperkalemia)

Differential Diagnosis of Hyperkalemic Periodic Paralysis

The clinical scenario that brings HyperKPP into the differential is typically an episodic, generalised, flaccid weakness — often with onset in childhood, recovery in hours, and a family history. The clinician's job is to systematically exclude mimics at every level of the neuro-axis (brain → spinal cord → peripheral nerve → neuromuscular junction → muscle) and then distinguish HyperKPP from other periodic paralyses and secondary causes of hyperkalemia-related weakness.

The best way to approach the differential is to think anatomically from "top to bottom," then narrow within the muscle/channelopathy category. The GC lecture provides an excellent scaffold for this.

GC 056 — "Generalised muscle weakness" classifies neuromuscular diseases into Neuropathy, NMJ disorders, and Myopathies (inherited vs acquired)" ^[6]. This is the high-yield framework for any episodic weakness question.

Approach Logic

The key discriminating features at each branch are: (1) UMN signs present → not a myopathy; (2) Sensory loss present → likely neuropathy, not pure muscle disease; (3) Fatigability → think NMJ; (4) Episodic + myotonia + family history → channelopathy. HyperKPP sits at the end of this pathway, in the "inherited channelopathy" box.

2. Systematic Differential Diagnosis

2.1 Other Periodic Paralyses (Most Important Differentials)

These are the closest mimics because they share the episodic flaccid weakness pattern. The distinguishing features are potassium level during attacks, myotonia, triggers, and demographics.

"Autosomal dominant mode, male predominance, attacks of flaccid paralysis lasting 6–24 hours with marked hypoK, spontaneously returned to normoK afterwards" ^[3]
Why it mimics HyperKPP: Both are AD-inherited channelopathies with episodic flaccid weakness, proximal > distal, sparing respiratory muscles.
How to distinguish:

Feature	HyperKPP	HypoKPP
Serum K⁺ during attack	High (5–6 mmol/L)	Low (often < 3.0 mmol/L)
Myotonia	Present	Absent
Age of onset	1–10 years	10–20 years ^[1]
Attack duration	Minutes to hours	6–24 hours ^[3]
Triggers	Fasting, cold, K⁺-rich food	High-CHO meals, exercise, stress ^[2]
Gene	SCN4A	CACNA1S (70%), SCN4A (~10%) ^[1]
Penetrance	Near-complete	Incomplete, especially in females ^[1]

Pathophysiological distinction: In HypoKPP, the defect is usually in the calcium channel (CACNA1S) → anomalous "gating pore" currents during hypokalemia-induced hyperpolarisation → paradoxical depolarisation of muscle membrane → inexcitability. The mechanism converges on the same final common pathway (depolarisation block), but the trigger direction is opposite (hypoK in HypoKPP vs hyperK in HyperKPP).

"Sporadic form of hypoK PP occurring in association with hyperthyroidism" ^[5]
"Mainly in Orientals, rare in Caucasians; predominantly in male patients; 25% vs 0.8%" ^[7]
Why it mimics HyperKPP: Episodic flaccid weakness, proximal > distal, motor only, spares respiratory/bulbar muscles. In Hong Kong, TPP is actually far more commonly encountered than HyperKPP because of the high prevalence of Graves' disease in the Asian population.
How to distinguish:

Feature	HyperKPP	TPP
Serum K⁺	High	Low (mean ~2.1 mmol/L, can be < 1.5) ^[5]
Thyroid function	Normal	Thyrotoxic (essential for pathogenesis) ^[5]
Family history of PP	Positive (AD)	Usually negative
Age of onset	1–10 y	20–39 y ^[5]
Sex	Equal	Male predominant (60:1) ^[8]
Myotonia	Present	Absent
Rebound hyperK after K⁺ Rx	Not typical	40–59% (because total body K⁺ is normal) ^[5]
Signs of thyrotoxicosis	Absent	Always preceded by thyrotoxic S/S ^[5]

Pathophysiological distinction: In TPP, thyroid hormones ↑Na⁺/K⁺-ATPase activity + ↑β₂-adrenergic sensitivity → excessive intracellular K⁺ shift → hypokalemia → membrane hyperpolarisation (then paradoxical depolarisation in susceptible individuals). The total body K⁺ is actually normal or high (it's a transcellular shift problem), which is why "regular potassium supplements are not necessary — only give patients when symptomatic" ^[7] and rebound hyperkalemia is a real risk.

"The classical example is a male with hyperthyroidism having a heavy carb meal at night, and the next morning cannot move when he wakes up" ^[7]

Hong Kong Exam Focus

In an HKUMed exam set in Hong Kong, if a young male presents with episodic weakness, TPP is statistically more likely than primary HyperKPP. Always check TFT. The HKU group even discovered the susceptibility locus for TPP at 17q24.3 ^[5] — this is a potential exam talking point.

"AD inheritance, due to voltage-gated Na⁺ channel mutation (17q23)" ^[2]
"Infantile onset, attacks of myotonia which ↑ in cold and hyperK, ↓ by hypoK, associated with flaccid weakness" ^[2]
Why it mimics HyperKPP: Both are SCN4A channelopathies, both have myotonia + weakness, both are triggered by cold. In fact, some families have overlapping phenotypes.
How to distinguish:

Feature	HyperKPP	PMC
Primary symptom	Weakness > myotonia	Myotonia > weakness
Myotonia behaviour	"Warm-up" phenomenon (improves with repeated contractions)	"Paradoxical" myotonia (worsens with repeated contractions)
Cold sensitivity	Present but not dominant	Dominant trigger
Weakness	Major feature	Less prominent; follows myotonia
Gene	SCN4A	SCN4A (different mutations in same gene)

Pathophysiological distinction: PMC mutations cause a more severe slowing of inactivation kinetics, particularly in cold → persistent Na⁺ current → sustained depolarisation → myotonia first, then weakness. The "paradoxical" myotonia (worsening with use) occurs because repeated activation keeps recruiting mutant channels that fail to inactivate, compounding the depolarisation.

A rare AD channelopathy caused by mutations in KCNJ2 (encoding Kir2.1, an inward-rectifier K⁺ channel).
Triad: (1) Periodic paralysis (can be hypo-, hyper-, or normokalemic), (2) Cardiac arrhythmias (prolonged QT, bidirectional VT), (3) Dysmorphic features (low-set ears, hypertelorism, clinodactyly, short stature).
How to distinguish from HyperKPP: Cardiac involvement is more prominent and dangerous; dysmorphic features are absent in HyperKPP; K⁺ can be variable (not reliably hyperkalemic).

These are not channelopathies — they are situations where genuine accumulation of total body K⁺ (or massive release from cells) causes hyperkalemia severe enough to impair muscle function.

"Muscle weakness usually occurs when [K⁺] > 8" ^[4]. In HyperKPP, weakness occurs at much milder levels (5–6 mmol/L) because the mutant channel is intrinsically sensitive to small K⁺ elevations. In secondary hyperkalemia, you typically need K⁺ > 7–8 mmol/L before overt weakness develops in a person with normal channels.

Cause	Mechanism	Distinguishing Features
Renal failure	Reduced renal K⁺ excretion → accumulating K⁺	Elevated creatinine/urea, oliguria/anuria, chronic disease course, NOT episodic
Hypoaldosteronism (Addison's, type 4 RTA, ACEi/ARB, spironolactone)	Reduced aldosterone → reduced renal K⁺ secretion	Hyponatremia + hyperkalemia + metabolic acidosis; drug history; adrenal insufficiency signs (hyperpigmentation, hypotension)
Tissue catabolism (rhabdomyolysis, tumour lysis syndrome, crush injury)	Massive release of intracellular K⁺ from damaged cells	Acute event, very high CK (rhabdomyolysis), uric acid/phosphate (TLS), trauma history
DKA / HHS / insulin deficiency	Lack of insulin → K⁺ cannot enter cells; hyperosmolality → K⁺ dragged out with water ^[9]	Hyperglycemia, acidosis, polyuria; diabetic history
Pseudohyperkalemia	K⁺ released from cells in the blood tube (haemolysis, thrombocytosis, leukocytosis, aged sample) ^[9]	Patient is asymptomatic; repeat sample is normal
Drugs (succinylcholine, digoxin, β-blockers, K⁺-sparing diuretics, NSAIDs, trimethoprim)	Various: block Na⁺/K⁺-ATPase (digoxin), block RAAS, shift K⁺ out of cells	Drug history; non-episodic; K⁺ normalises on drug withdrawal
Massive blood transfusion	Stored RBCs leak K⁺ over time	Context of transfusion

Exam Pitfall — Pseudohyperkalemia

Pseudohyperkalemia must always be excluded first. If the blood sample was haemolysed, from an EDTA tube (which itself contains K⁺), or from a patient with extreme thrombocytosis or leukocytosis (as in leukaemia — "K⁺ moves out of the plates after clotting has occurred" or "cell fragility" in leukaemia ^[9]), the K⁺ is artefactually high. The patient is well, and a repeat fresh sample in the correct tube is normal. Always check the lab comment for "haemolysed specimen."

2.3 Differential Diagnosis of Generalised Quadriparesis (Non–Periodic Paralysis Causes)

When the presentation is acute generalised weakness rather than clearly episodic, you must consider non-channelopathy causes. The Felix Lai notes provide a useful list ^[1]:

"Differential diagnosis of generalized weakness (quadriparesis): Myasthenia gravis, Botulism, Guillain-Barré syndrome, Transverse myelitis, Secondary hypokalemic PP (TPP, hyperaldosteronism, RTA)" ^[1]

"Bilateral progressive symmetrical weakness of the limbs (cardinal feature), generalized areflexia or hyporeflexia (cardinal feature), pain and paraesthesia" ^[10]
Why it might mimic HyperKPP: Ascending flaccid weakness with areflexia — both can present as a child who "can't get up."
How to distinguish:

Feature	HyperKPP	GBS
Onset	Minutes to hours, recurrent	Progresses over ~2 weeks, monophasic ^[10]
Sensory	Intact	Paraesthesia in hands/feet ^[10]
Respiratory	Spared	May affect respiratory muscles
Autonomic	Not affected	Tachycardia, BP instability, ileus ^[10]
Recovery	Hours (spontaneous)	Weeks to months
CSF	Normal	Albuminocytological dissociation (↑protein, normal cells)
NCS/EMG	Myotonic discharges (HyperKPP)	Demyelinating or axonal neuropathy pattern
Serum K⁺	High	Normal
Family history	Positive (AD)	Negative
Preceding event	Triggers (fasting, cold, exercise)	Infection (Campylobacter, CMV, EBV) 1–4 weeks before

Autoimmune NMJ disorder with anti-AChR (or anti-MuSK) antibodies.
How to distinguish: Fatigability is the hallmark (weakness worsens with repeated use, improves with rest — opposite to myotonia which improves with repeated contraction in HyperKPP). Ptosis and diplopia (ocular involvement) are very common in MG but essentially absent in HyperKPP. No K⁺ abnormality. Positive Tensilon test (edrophonium) and anti-AChR antibodies clinch the diagnosis.

Clostridium botulinum toxin blocks acetylcholine release at the NMJ (presynaptic).
How to distinguish: Descending paralysis (cranial nerves first — bulbar palsy, diplopia, then limbs), pupils dilated and fixed, autonomic dysfunction. History of contaminated food (wound botulism in IV drug users). K⁺ normal. No myotonia.

How to distinguish: UMN signs (hyperreflexia, Babinski, spasticity) below the lesion — fundamentally different from the flaccid, areflexic weakness of HyperKPP. Sensory level present. Bladder/bowel dysfunction early. MRI spine is diagnostic.

"Polymyositis (proximal), Dermatomyositis (proximal)" ^[10]
How to distinguish: Progressive (not episodic) proximal weakness. Very high CK persistently. Skin rash in DM (heliotrope, Gottron's papules). EMG shows irritable myopathy (fibrillations, positive sharp waves) but NOT myotonic discharges. Muscle biopsy shows inflammatory infiltrate.

"Duchenne, Becker, FSHMD, Limb-girdle" ^[10]
How to distinguish: Progressive, non-episodic weakness. Pseudohypertrophy (Duchenne). Onset and pattern depend on subtype. No K⁺ abnormality. No myotonia (except myotonic dystrophy, which has its own distinct features — see below).

"CTG expansion at 19q13.3, AD inheritance" ^[2]
Why it might be confused: Both have myotonia. Both are AD.
How to distinguish: MyD has distal weakness (not proximal), facial wasting (myopathic facies), cataracts, cardiac conduction defects, diabetes, testicular atrophy — it is a multisystem disease ^[2]. HyperKPP is purely a skeletal muscle disease with episodic weakness and no systemic involvement. MyD is progressive, not episodic.

Statins (HMG-CoA reductase inhibitors), corticosteroids ^[10]
How to distinguish: Drug history, progressive (not episodic), CK may be elevated (statins), no K⁺ abnormality, no myotonia.

"Cushing's syndrome (proximal), Hyperthyroidism/Hypothyroidism (proximal)" ^[10]
How to distinguish: These cause chronic proximal weakness, not episodic attacks. Features of the underlying endocrine disorder are present. Note: hyperthyroidism can cause both chronic thyrotoxic myopathy (persistent, insidious) and TPP (episodic) — they are separate entities.

Disorders of glycogen metabolism (e.g., McArdle disease — myophosphorylase deficiency), lipid metabolism (e.g., CPT II deficiency), mitochondrial myopathies.
How to distinguish: Exercise intolerance (rather than episodic weakness at rest), myoglobinuria after exertion (McArdle), "second wind" phenomenon, no K⁺ abnormality, specific enzyme testing/genetics.

"RYR1 or DHP mutation (AR >> AD) → unregulated Ca²⁺ influx from SR → sustained muscle contraction → ↑↑metabolism → metabolic acidosis, rhabdomyolysis, hyperthermia" ^[2]
"Triggered by anaesthetic agents (halothane, isoflurane), muscle relaxants (succinylcholine)" ^[2]
Why mentioned here: Both MH and HyperKPP can be triggered by anaesthesia, and both involve muscle rigidity/dysfunction under anaesthesia. Some SCN4A mutations may confer susceptibility to both.
How to distinguish: MH presents with hyperthermia, rigidity (not flaccidity), masseter spasm, metabolic/respiratory acidosis, rhabdomyolysis, and hyperkalemia — in the operating theatre during or immediately after anaesthesia ^[2]^[11]. HyperKPP presents with flaccid weakness (not rigidity) and mild hyperkalemia, usually outside the perioperative setting.

Anaesthesia Safety

Patients with known HyperKPP should be flagged for anaesthesia risk. Succinylcholine (a depolarising neuromuscular blocker) can cause massive K⁺ release and should be avoided. Non-depolarising agents are preferred. This overlaps with the precautions for malignant hyperthermia — "Genetic conditions predisposing to increased risk of anaesthesia: pseudocholinesterase deficiency, malignant hyperthermia" ^[11], and channelopathies including HyperKPP should be added to that mental list.

When a patient (especially a child or young adult) presents with episodic flaccid weakness, the practical bedside approach is:

Step	Action	Rationale
1. Confirm the attack pattern	History: episodic? Duration? Triggers? Recovery? Family history?	Episodic + full recovery + FHx = strongly suggests periodic paralysis. GBS does NOT fully recover in hours.
2. Check serum K⁺ during an attack	Stat electrolytes during an episode	HyperKPP: K⁺ elevated (5–6 mmol/L). HypoKPP/TPP: K⁺ low. This is THE key branch point.
3. Check K⁺ between attacks	Electrolytes when well	Primary PP: K⁺ is NORMAL between attacks ^[3]. Secondary hyperkalemia (renal failure, Addison's): K⁺ remains elevated chronically.
4. Thyroid function tests	TFT (TSH, fT4)	Excludes TPP. "Always preceded by thyrotoxic S/S (thyrotoxic state essential for pathogenesis)" ^[5]
5. Look for myotonia	Examine for percussion/grip myotonia; EMG	Myotonia is present in HyperKPP but NOT in HypoKPP or TPP — this is a clinical pearl
6. Exclude secondary causes	RFT (renal failure?), drug history, CK (rhabdomyolysis?), glucose (DKA?), cortisol (Addison's?)	Exclude non-channelopathy causes of hyperkalemia
7. Genetic testing	SCN4A mutation analysis	Confirmatory for HyperKPP
8. Provocative testing	KCl loading test (in specialist centre, with cardiac monitoring)	Provokes an attack in HyperKPP; rarely done now that genetic testing is available ^[2]

Category	Condition	K⁺	Episodic?	Myotonia?	Key Distinguishing Feature
Primary PP	HyperKPP	↑	Yes	Yes	Childhood onset, AD, SCN4A, cold/fasting triggers
	HypoKPP	↓	Yes	No	Teenage onset, CHO/exercise triggers, longer attacks
	TPP	↓	Yes	No	Asian male, thyrotoxicosis, rebound hyperK risk
	Paramyotonia Congenita	Normal/↑	Yes	Yes (paradoxical)	Cold-dominant, myotonia worsens with use
	Andersen-Tawil	Variable	Yes	No	Cardiac arrhythmias + dysmorphic features
Secondary hyperK	Renal failure	↑↑	No	No	Elevated creatinine, chronic
	Addison's disease	↑	No	No	Hyperpigmentation, hyponatremia, low cortisol
	Drugs (ACEi, K⁺-sparing diuretics)	↑	No	No	Drug history
	Rhabdomyolysis / TLS	↑↑	No	No	Very high CK, urate; acute context
	DKA	↑	No	No	Hyperglycemia, acidosis, diabetic Hx
	Pseudohyperkalemia	"↑"	No	No	Haemolysed sample; patient asymptomatic
Other weakness	GBS	N	No (progressive)	No	Ascending, sensory, CSF protein↑, post-infection
	MG	N	Fluctuating	No	Fatigability, ocular, anti-AChR Ab
	Transverse myelitis	N	No	No	UMN signs, sensory level, MRI lesion
	Inflammatory myopathy	N	No (chronic)	No	CK↑↑, skin rash (DM), biopsy
	Myotonic dystrophy	N	No (chronic)	Yes	Distal weakness, multisystem (cataracts, DM, cardiac)
	Malignant hyperthermia	↑	No	No (rigidity)	Perioperative, hyperthermia, rigidity, rhabdomyolysis

High Yield Summary — Differential Diagnosis of HyperKPP

The single most important investigation to differentiate periodic paralyses is serum K⁺ during an attack: ↑ = HyperKPP (or secondary hyperK); ↓ = HypoKPP or TPP.
Myotonia distinguishes HyperKPP from HypoKPP and TPP (both lack myotonia).
TFT must always be checked to exclude TPP — especially in Hong Kong where TPP in young Asian males is far more common than primary periodic paralysis.
Normal K⁺ between attacks distinguishes primary PP from secondary hyperkalemia (renal failure, Addison's, drugs).
Age of onset helps: 1–10 y (HyperKPP) → 10–20 y (HypoKPP) → > 20 y (TPP).
GBS is the main non-myopathic mimic — distinguished by monophasic progressive course, sensory involvement, autonomic dysfunction, and CSF findings.
Always consider pseudohyperkalemia (haemolysed sample, EDTA contamination) before diagnosing true hyperkalemia.
Anaesthesia risk: HyperKPP patients — avoid succinylcholine (risk of severe hyperkalemia and sustained depolarisation).

Active Recall - Differential Diagnosis of HyperKPP

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Periodic Paralysis comparison table and DDx of quadriparesis (p. 1652, 1655) ^[2] Senior notes: Ryan Ho Neurology.pdf — Periodic paralysis, ion channelopathies, myotonic dystrophy, malignant hyperthermia (p. 191–194) ^[3] Lecture slides: Chemical Pathology Seminar_Potassium.pdf (p. 32–33) ^[4] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (p. 27, 29) ^[5] Senior notes: Ryan Ho Endocrine.pdf — TPP section (p. 29) ^[6] Lecture slides: GC 056. Generalized muscle weakness.pdf (p. 1, 9) ^[7] Senior notes: Block A - I am losing weight and sweating all the time_ causes of severe, weight loss; thyrotoxicosis; hypothyroidism.pdf (p. 34–35) ^[8] Senior notes: Maksim Medicine Notes.pdf — TPP section (p. 95) ^[9] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Hyperkalemia etiology (p. 50) ^[10] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf — DDx of myopathies, GBS (p. 547, 706) ^[11] Senior notes: Gen Clerk Anaes + Microbiology Summary.pdf — Genetic conditions and anaesthesia risk (p. 4)

Diagnostic Criteria, Algorithm and Investigations for Hyperkalemic Periodic Paralysis

1. Diagnostic Criteria

There is no single universally accepted "diagnostic criteria checklist" for HyperKPP in the way that, say, the Jones criteria exist for rheumatic fever. Instead, the diagnosis is made by a convergence of clinical features + ictal electrolyte findings + exclusion of secondary causes ± genetic confirmation. The most widely used diagnostic framework (adapted from the European Neuromuscular Centre [ENMC] and International Periodic Paralysis Consortium) is as follows:

A diagnosis of HyperKPP is probable when ALL of the following are met:

#	Criterion	Rationale (First Principles)
1	≥ 2 episodes of flaccid weakness with documented serum K⁺ > 5.0 mmol/L during at least one attack	A single episode could be coincidental; recurrence establishes the "periodic" nature. The hyperkalemia during attack is the defining biochemical hallmark — it separates HyperKPP from HypoKPP and TPP.
2	Onset in the first or second decade of life (typically 1–10 years) ^[1]	Late onset makes secondary hyperkalemia or TPP far more likely.
3	Autosomal dominant family history OR de novo presentation with compatible features	Near-complete penetrance ^[1] means most mutation carriers are clinically affected; a negative FHx should prompt consideration of de novo mutation or alternative diagnoses.
4	Normal serum K⁺ between attacks	This distinguishes primary periodic paralysis from chronic hyperkalemia (renal failure, Addison's), where K⁺ is persistently elevated ^[3]^[12].
5	Myotonia (clinical or electrophysiological) between or early in attacks	"Intermittent myotonia accompanied by high serum K⁺ level" ^[1]. Myotonia is the key clinical feature that separates HyperKPP from HypoKPP and TPP (both lack myotonia).
6	Absence of secondary causes of hyperkalemia (normal RFT, no offending drugs, no tissue catabolism, no adrenal insufficiency)	Must exclude the far more common reasons for hyperkalemia ^[9]^[12].
7	Normal thyroid function	Excludes TPP. Essential in the Hong Kong context where TPP is common ^[5].

A diagnosis is definite when the above clinical criteria are met AND a pathogenic SCN4A mutation is identified on genetic testing.

Why There Are No 'Hard' Criteria

HyperKPP is too rare for formal sensitivity/specificity validation studies of diagnostic criteria. In practice, the diagnosis rests on pattern recognition: episodic flaccid weakness + hyperkalemia during attacks + normokalemia between attacks + myotonia + family history + exclusion of secondary causes. Genetic testing is the gold standard confirmation.

Feature	Comment
Attack triggers: exercise, cold, fasting, K⁺-rich meals ^[2]^[3]	Typical triggers raise extracellular K⁺ or slow channel inactivation
Attack duration: spontaneously resolves over a few hours ^[3]	Shorter than HypoKPP (6–24 h)
Spares respiratory and bulbar muscles ^[2]	Atypical respiratory involvement should trigger search for alternative dx (e.g., GBS, MG)
Proximal > distal, LL > UL ^[2]	Standard pattern for all periodic paralyses
Relief by mild exercise or carbohydrate intake	Mild exercise activates Na⁺/K⁺-ATPase → drives K⁺ back into cells → repolarises membrane; carbohydrate → insulin release → same mechanism
Late progressive proximal myopathy (4th–6th decade) ^[2]	Cumulative vacuolar myofibre damage

The algorithm below walks through the clinical reasoning from "patient presents with episodic weakness" to "confirmed HyperKPP." It integrates the approaches from multiple sources.

"Rule out factitious ↑[K⁺] — most common cause. Repeat sample if query." ^[12]

Step 1 of hyperkalemia workup: "Exclusion of pseudohyperkalemia, drug-induced hyperkalemia and other rare causes" ^[9]

Key Branch Points — Exam Focus

The three critical branch points in the algorithm:

Serum K⁺ during attack → high vs low immediately splits into HyperKPP vs HypoKPP/TPP
K⁺ between attacks → normal (primary PP) vs persistently elevated (secondary cause)
TFT → must be checked in every case of periodic paralysis to exclude TPP

These three tests — ictal K⁺, interictal K⁺, and TFT — are the minimum essential investigations.

3. Investigation Modalities

3.1 Bedside Investigations

Why: Hyperkalemia — even mild — can cause cardiac conduction abnormalities and arrhythmias. ECG is the most immediately important investigation during an acute attack.

When to do it: "Perform ECG if > 6.5 mmol/L" ^[12], but in practice should be done for any patient presenting with weakness + hyperkalemia.

Key Findings and Interpretation:

The ECG changes of hyperkalemia follow a predictable progression that mirrors the effect of extracellular K⁺ on cardiac myocyte membrane potential:

K⁺ Level	ECG Change	Pathophysiological Explanation
5.5–6.5 mmol/L	Tall, peaked ("tented") T waves with narrow base	Extracellular hyperK → accelerated repolarisation of ventricular myocytes → rapid K⁺ efflux during phase 3 → T wave becomes tall and narrow
6.5–7.0 mmol/L	Flattened P waves, prolonged PR interval	Atrial myocytes are more sensitive to hyperK than ventricular → atrial conduction slows → P wave flattens and PR interval lengthens
7.0–8.0 mmol/L	Widened QRS complex	Depolarisation of resting membrane → inactivation of Na⁺ channels → slower ventricular conduction → QRS widens
> 8.0 mmol/L	Loss of P wave, sine-wave pattern	Complete atrial standstill; QRS merges with T wave → sine wave
> 10 mmol/L	Ventricular fibrillation / asystole	Complete inexcitability of cardiac tissue

"ECG: peaked T, widening of QRS, loss of P, sine wave, asystole" ^[4]

"ECG changes of hyperK: 6–7 mmol/L (tall, peaked T waves), 8–10 mmol/L (aberrant QRS complexes), 11 mmol/L (fusion of QRS and T waves), 10–12 mmol/L (ventricular fibrillation)" ^[12]

In HyperKPP specifically: Because the hyperkalemia is typically mild (5.0–6.0 mmol/L), you most commonly see only peaked T waves. Life-threatening sine-wave/VF patterns are rare in HyperKPP (unlike renal failure hyperK where K⁺ can reach 8–10 mmol/L). However, cardiac monitoring during attacks is still mandatory because:

Some attacks can produce K⁺ > 6.0 mmol/L
Individual susceptibility to arrhythmias varies
Rate of K⁺ rise matters (acute rise is more dangerous than chronic) ^[4]

Percussion myotonia: Tap the thenar eminence sharply with a tendon hammer → look for sustained dimpling/contraction and slow relaxation (takes > 3 seconds to relax). This is due to the hyperexcitable membrane firing repetitive action potentials in response to the mechanical stimulus.

Grip myotonia: Ask the patient to make a tight fist and then rapidly open the hand → observe delayed finger extension. The mutant Na⁺ channels fire repetitively upon initial contraction, delaying relaxation.

"Warm-up" phenomenon: Myotonia improves with repeated contractions (unlike paramyotonia congenita where it worsens). This is because repeated activation gradually inactivates even the mutant channels, reducing the persistent Na⁺ current.

3.2 Blood Investigations

The single most important blood test. Must be drawn during an attack if possible.

Analyte	Expected Finding in HyperKPP	Interpretation
Serum K⁺	> 5.0 mmol/L (typically 5.0–6.0 mmol/L)	K⁺ efflux from muscle through depolarised membranes. Higher levels (> 7–8) suggest secondary hyperkalemia rather than HyperKPP.
Serum K⁺ between attacks	Normal (3.5–5.0 mmol/L)	This is critical — persistent hyperkalemia between attacks points to secondary causes (renal failure, Addison's, drugs) ^[9]^[12]
Na⁺, Cl⁻, HCO₃⁻	Usually normal	No associated acid-base disturbance in primary HyperKPP (unlike DKA which has acidosis, or Addison's which has hyponatremia + hyperkalemia)
Ca²⁺, Mg²⁺, PO₄³⁻	Normal	Abnormalities suggest alternative diagnoses (e.g., hypoMg causing refractory hypoK ^[12])

"Exclude pseudohyperkalemia (esp. normal RFT): haemolysis, thrombocythaemia, EDTA, drip arm" ^[8]

Practical Pearl: When sending a sample during an attack, ensure:

Correct tube (lithium heparin for plasma K⁺, NOT EDTA tube — "EDTA tube contains K⁺" → falsely elevated ^[9])
Avoid tourniquet clenching (causes K⁺ release from forearm muscles)
Process promptly (aged samples leak K⁺ from cells)
If thrombocytosis or leukocytosis present (e.g., leukaemia), use plasma (not serum) to avoid in-vitro K⁺ release during clotting — "K⁺ moves out of the plates after clotting has occurred" ^[9]

Analyte	Expected	Interpretation
Creatinine, Urea	Normal	Renal failure is the most common cause of hyperkalemia ^[8]^[12]. Normal RFT excludes this and supports a primary channelopathy.
eGFR	Normal	Preserved kidney function

Analyte	Expected in HyperKPP	Interpretation
TSH	Normal	Excludes thyrotoxicosis
fT4, fT3	Normal	"Always preceded by thyrotoxic S/S (thyrotoxic state essential for pathogenesis)" ^[5] — a normal TFT rules out TPP

Investigations for TPP: "Bloods: electrolytes (K↓↓), CPK↑, TFT" ^[8]. The TFT is the definitive test to distinguish TPP from primary periodic paralysis.

Must-Do for Every Episodic Weakness Patient in Hong Kong

Always check TFT. In the Hong Kong clinical context, TPP in young Asian males is far more common than primary HyperKPP or HypoKPP. Missing thyrotoxicosis as the underlying cause is a dangerous error because the definitive treatment (anti-thyroid therapy) is completely different from managing a channelopathy. Even if K⁺ is high during an attack (which would be unusual for TPP), check TFT — Ryan Ho notes that HyperKPP "may also be accompanied with thyrotoxicosis" ^[3].

Expected	Interpretation
Normal or mildly elevated during attacks	During attacks, some muscle fibre damage occurs from sustained depolarisation → mild CK leak. Very high CK (> 10× ULN) suggests rhabdomyolysis or inflammatory myopathy rather than HyperKPP. CK may be chronically mildly elevated in patients with fixed myopathy.

Periodic paralysis (hyperK): "Serum K, TFT" as key investigations ^[13]. "Episodic weakness, normal between attacks → serum K, TFT" ^[13].

Test	Purpose
Glucose	Exclude DKA/HHS as a cause of hyperkalemia — "Rule out DKA" ^[8]. In DKA, insulin deficiency + hyperosmolality drives K⁺ out of cells ^[9].
VBG (pH, HCO₃⁻, lactate)	Exclude metabolic acidosis. "RFT and VBG: to differentiate renal impairment and acidosis from other causes" ^[8]. Acidosis causes transcellular K⁺ shift (H⁺ enters cells via H⁺/K⁺ exchange → K⁺ exits).

Test	Purpose
8 AM cortisol ± ACTH	Exclude adrenal insufficiency (Addison's disease), which causes hyperkalemia + hyponatremia due to aldosterone deficiency. Only needed if hyperkalemia is persistent between attacks or there are suggestive signs (hyperpigmentation, hypotension, weight loss).

Not a "lab test" per se, but one of the most important diagnostic steps:

"Check drug history: K supplement, NSAID, ACEi/ARB, MRA, digoxin" ^[8]

Drug Class	Mechanism of Hyperkalemia
K⁺ supplements / K⁺-sparing diuretics (spironolactone, amiloride, triamterene)	Direct K⁺ loading or reduced renal excretion
ACEi / ARB	Block RAAS → reduced aldosterone → reduced renal K⁺ secretion
NSAIDs	Inhibit prostaglandin-mediated renin release → ↓aldosterone
Digoxin	Inhibits Na⁺/K⁺-ATPase → K⁺ cannot enter cells
Trimethoprim	Blocks ENaC in collecting duct (like amiloride)
β-blockers	Block β₂-mediated cellular K⁺ uptake + block renin release
Succinylcholine	Depolarises muscle → massive K⁺ efflux

3.3 Electrophysiological Investigations

Purpose: To detect myotonia (which may be subclinical) and characterise the myopathic pattern.

Key Findings:

Finding	Significance
Myotonic discharges	Waxing-and-waning, high-frequency repetitive discharges with a characteristic "dive-bomber" sound on audio. Present BETWEEN attacks in HyperKPP. This is a key finding — "Dx: weakness with mild hyperK, myotonia between attacks" ^[2]. It confirms the channelopathy and distinguishes HyperKPP from HypoKPP (no myotonia) and TPP (no myotonia).
Decreased CMAP amplitude during attacks	Compound muscle action potential decreases because fewer muscle fibres can generate action potentials (depolarisation block). Returns to normal between attacks (early disease).
Myopathic MUPs (late disease)	Short-duration, low-amplitude, polyphasic motor unit potentials — indicating myofibre loss from chronic vacuolar myopathy.
Fibrillation potentials (late disease)	Denervation-like activity from severely damaged fibres.

Provocation during EMG (specialised centres): EMG can be performed while the patient is subjected to a mild provocative stimulus (e.g., local cooling of the limb) to unmask myotonic discharges or demonstrate CMAP decrement in real time.

Finding	Significance
Normal motor and sensory NCS	Confirms the problem is at the muscle level, not nerve. Rules out GBS (which shows demyelinating pattern — prolonged distal latency, conduction block, ↑F-wave latency) and other neuropathies.

Approach to generalised weakness — Muscle diseases investigations: "CK, lactate, EMG, regional US/MRI, muscle biopsy, genetic testing" ^[14]

This is a specialised electrophysiological provocative test used in centres experienced with periodic paralysis:

Protocol: The patient performs maximal voluntary contraction (e.g., abductor digiti minimi) for 5 minutes, then rests. CMAP amplitude is measured every 1–2 minutes for 40–60 minutes post-exercise.
In HyperKPP: Post-exercise CMAP amplitude increases initially (because exercise activates Na⁺/K⁺-ATPase, normalising the membrane), then decreases > 40% during the rest period (as the pump activity wanes and K⁺ re-accumulates extracellularly).
Value: Non-invasive, can be done between attacks, helps distinguish different subtypes of periodic paralysis. Has ~70–80% sensitivity.

"SCN4A mutation" — the confirmatory investigation ^[1]^[2]

Aspect	Detail
Gene	SCN4A (chromosome 17q23.3)
Method	Targeted Sanger sequencing of known hotspot exons (exons 12, 13, 22, 24) or, increasingly, next-generation sequencing (NGS) gene panels for channelopathies (panels typically include SCN4A, CACNA1S, KCNJ2, KCNJ5, SCN5A, etc.)
Common mutations	T704M (~50%), M1592V (~30%), other rare variants
Sensitivity	~60–80% of clinically diagnosed HyperKPP cases have identifiable SCN4A mutations. A negative result does NOT rule out HyperKPP if the clinical picture is convincing (there may be novel/uncharacterised variants or variants in regulatory regions).
Turnaround	Weeks to months (not useful acutely, but essential for definitive diagnosis and genetic counselling)
Genetic counselling	Autosomal dominant ^[1]^[3] → 50% risk of transmission to offspring. Near-complete penetrance means most carriers will be clinically affected. Offer testing to at-risk family members.

When Genetic Testing Is Negative

If a patient has a compelling clinical picture but negative SCN4A testing, consider: (1) Whole-exome sequencing to identify novel variants; (2) Testing for KCNJ2 (Andersen-Tawil syndrome) or other channelopathy genes; (3) Re-evaluate the diagnosis — could this be secondary hyperkalemic weakness misdiagnosed as primary PP?

3.5 Provocative Testing (Largely Historical, Rarely Done Now)

Protocol: Under cardiac monitoring (ICU/HDU), oral KCl 0.05–0.15 g/kg is given. Serum K⁺ and muscle strength are assessed serially.
Positive test: Development of flaccid weakness with a rise in serum K⁺.
"Provocative testing by KCl" ^[2] — mentioned as a diagnostic modality in Ryan Ho's neurology notes.
Why rarely done now: Risk of cardiac arrhythmia; genetic testing is safer and more specific. Only performed in specialist centres when genetic testing is negative and clinical suspicion remains high.

Immersion of a limb in cold water while monitoring CMAP → demonstrates cold-induced CMAP decrement. More useful for paramyotonia congenita but can also trigger attacks in HyperKPP.

Finding	Significance
Vacuolar myopathy	Sarcoplasmic vacuoles visible on H&E staining — represent dilated T-tubules and sarcoplasmic reticulum due to chronic membrane instability. More prominent in older patients with fixed myopathy.
Tubular aggregates	Aggregates of tubular structures derived from sarcoplasmic reticulum — a non-specific finding seen in several channelopathies.
Fibre size variability	Reflects ongoing damage and regeneration cycles.

When to consider biopsy: Only if the diagnosis remains uncertain after electrolytes, EMG, and genetic testing — e.g., to exclude inflammatory myopathy or metabolic myopathy. It is not a first-line investigation for suspected HyperKPP.

Investigation	Excludes	Expected in HyperKPP
Full blood count	Leukocytosis (pseudohyperK), myeloproliferative disease	Normal
Blood glucose	DKA/HHS	Normal
Urate, LDH, PO₄³⁻	Tumour lysis syndrome / pseudohyperK from haemolysis — "Check for intracellular constituents such as AST, LDH and urate for pseudohyperkalemia" ^[9]	Normal
TTKG (Trans-Tubular K⁺ Gradient)	Differentiates renal vs extrarenal cause of hyperK. "Aldosterone defect if TTKG < 7 (normal > 10)" ^[8]	Not typically needed if K⁺ is normal between attacks
Urine electrolytes	Renal K⁺ handling abnormalities (Bartter, Gitelman — but these cause hypoK)	Normal

Priority	Investigation	Key Finding
Immediate (during attack)	Serum electrolytes (K⁺, Na⁺, Cl⁻, HCO₃⁻, Ca²⁺, Mg²⁺, PO₄³⁻)	K⁺ elevated > 5.0 (typically 5–6)
	ECG	Peaked T waves ± PR prolongation
	Blood glucose	Normal (excludes DKA)
	VBG	Normal pH (excludes acidosis-driven hyperK)
Urgent (same day)	RFT (Cr, urea, eGFR)	Normal (excludes renal failure)
	TFT (TSH, fT4)	Normal (excludes TPP)
	CK	Normal or mildly elevated
	Full drug history	No offending agents
Between attacks	Repeat serum K⁺	Normal (normokalemia between attacks)
	EMG	Myotonic discharges ("dive-bomber" sound)
	NCS	Normal (excludes neuropathy)
	Long exercise test (specialist)	Post-exercise CMAP decrement > 40%
Definitive	SCN4A genetic testing	Pathogenic mutation (e.g., T704M, M1592V)
If needed	8 AM cortisol ± ACTH	Normal (excludes Addison's)
	Muscle biopsy	Vacuolar myopathy (late disease)
	Provocative KCl loading (specialist)	Weakness with hyperK

High Yield Summary — Diagnosis of HyperKPP

No single diagnostic criterion exists — diagnosis is clinical + biochemical + genetic.
Three essential investigations during an acute attack: serum K⁺ (high), ECG (peaked T waves), TFT (normal, excludes TPP).
Serum K⁺ must be normal between attacks — persistent hyperkalemia = secondary cause (renal failure, Addison's, drugs).
Always exclude pseudohyperkalemia first: haemolysis, EDTA tube, thrombocytosis, leukocytosis ^[8]^[9]^[12].
Myotonic discharges on EMG between attacks are a key supportive finding — absent in HypoKPP and TPP.
Genetic testing (SCN4A) is the definitive confirmatory test — identifies T704M (~50%) or M1592V (~30%).
Provocative KCl loading is historical and rarely done now; genetic testing has replaced it.
ECG progression of hyperkalemia: peaked T → flat P / long PR → wide QRS → sine wave → asystole ^[4]^[8]^[12].
The long exercise test (McManis protocol) is a non-invasive electrophysiological test that can support the diagnosis between attacks.
Muscle biopsy (vacuolar myopathy) is reserved for diagnostic uncertainty.

Active Recall - Diagnosis and Investigations of HyperKPP

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Periodic Paralysis comparison table (p. 1652) ^[2] Senior notes: Ryan Ho Neurology.pdf — Periodic paralysis, channelopathies (p. 191–194) ^[3] Lecture slides: Chemical Pathology Seminar_Potassium.pdf (p. 32–33) ^[4] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (p. 27, 29) ^[5] Senior notes: Ryan Ho Endocrine.pdf — TPP section (p. 29) ^[8] Senior notes: Maksim Medicine Notes.pdf — Hyperkalemia investigations and management (p. 210); TPP (p. 95) ^[9] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Hyperkalemia etiology and diagnostic algorithm (p. 50, 53) ^[12] Senior notes: Ryan Ho Chemical Path.pdf — Hyperkalemia workup (p. 14, 19) ^[13] Senior notes: Maksim Medicine Notes.pdf — Metabolic myopathy table (p. 276) ^[14] Senior notes: Adrian Lui Pediatrics Notes.pdf — Approach to generalised weakness, investigations table (p. 134)

Management of Hyperkalemic Periodic Paralysis

Managing HyperKPP requires thinking about two distinct time frames with fundamentally different goals:

Phase	Goal	Logic
Acute attack	Terminate the attack, protect the heart, restore muscle function	The immediate problem is hyperkalemia → depolarisation block → paralysis ± cardiac risk. You need to shift K⁺ back into cells or antagonise its cardiac effects.
Chronic / prophylactic	Reduce attack frequency and severity, prevent long-term myopathy	The underlying channelopathy cannot be "cured" — the mutant SCN4A channel is permanent. Management is about avoiding triggers and pharmacologically reducing the impact of those triggers.

A third, overarching consideration is genetic counselling and lifestyle modification, since this is a lifelong inherited condition.

The key conceptual difference from managing secondary hyperkalemia (e.g., renal failure) is that in HyperKPP the total body K⁺ is normal — the hyperkalemia is from transcellular K⁺ shift out of muscle. Therefore, treatments that remove K⁺ from the body (dialysis, ion-exchange resins) are generally not needed and could cause rebound hypokalemia. The strategy is to shift K⁺ back into cells and stabilise the muscle membrane.

3. Acute Attack Management

Action	Rationale
Cardiac monitoring (continuous ECG)	Even mild hyperkalemia (5–6 mmol/L) can occasionally cause arrhythmias in susceptible individuals. Must detect peaked T waves, PR prolongation, or QRS widening early.
Stat serum K⁺	Quantify the degree of hyperkalemia to guide urgency of treatment.
Check glucose	Exclude DKA as a cause of hyperkalemia. Also important because glucose/insulin therapy is a treatment option.
Ensure IV access	For potential IV calcium or insulin-dextrose if needed.

"IV Ca gluconate 10% 10mL over 2–5min → Repeat if no effect in 5min. If stable asymptomatic: IV Ca gluconate 10% 10mL in 100mL NS infusion over 1 hour" ^[8]

IV Calcium Gluconate 10% — 10 mL (2.2 mmol Ca²⁺) over 2–5 minutes

Mechanism: Calcium does NOT lower serum K⁺. Instead, it raises the threshold potential of cardiac myocytes, making them less susceptible to the depolarising effects of hyperkalemia. Think of it as widening the gap between the resting membrane potential and the threshold → restores the safety margin for action potential generation → protects against arrhythmias.
Why calcium gluconate, not calcium chloride? Calcium chloride delivers more ionised Ca²⁺ per mL but causes severe tissue necrosis if it extravasates from a peripheral IV. Calcium gluconate is safer peripherally. In a central line setting, calcium chloride can be used.
Onset: 1–3 minutes. Duration: ~30–60 minutes. Can be repeated.
Contraindication: "Omit if digoxin toxicity suspected" ^[8] — calcium potentiates digoxin's effect on the heart (both increase intracellular Ca²⁺) and can cause fatal arrhythmias in digitalis toxicity.

Exam Point: Calcium Does NOT Lower K⁺

A very common student error is saying "calcium gluconate lowers potassium." It does NOT. It stabilises the cardiac membrane. You still need a separate intervention to actually shift K⁺ into cells or remove it from the body.

3.3 Treatments That Drive K⁺ Into Cells (Primary Strategy in HyperKPP)

Because the hyperkalemia in HyperKPP is from transcellular shift (K⁺ leaking out of muscle), the logical treatment is to reverse that shift — drive K⁺ back into cells. This is different from renal failure hyperkalemia where you ultimately need to remove K⁺ from the body.

"Mx: sugar/mild exercise, thiazide, β₂ agonist, IV Ca (acute)" ^[2]

Drug: Nebulised salbutamol 10–20 mg (in 3 mL NS) — note this is much higher than the bronchodilator dose (2.5–5 mg) because the target is a systemic metabolic effect, not bronchodilation.
Mechanism: β₂-adrenergic receptor stimulation → activates the Na⁺/K⁺-ATPase pump (via cAMP/PKA pathway) → drives K⁺ into cells → lowers extracellular K⁺ → repolarises the muscle membrane → restores excitability → weakness improves.
Why β₂-agonists are particularly logical in HyperKPP: The fundamental problem is K⁺ leaking OUT of muscle via the mutant Na⁺ channel. By supercharging the Na⁺/K⁺-ATPase, you actively pump K⁺ back in, counteracting the leak.
Onset: 15–30 minutes. Duration: ~2–4 hours. Expected K⁺ drop: 0.5–1.0 mmol/L.
Side effects: Tachycardia, tremor, mild hypokalemia if excessive.
Contraindications: Significant cardiac arrhythmias (the tachycardia could worsen unstable arrhythmia), known allergy.

"Mx: sugar/mild exercise" ^[2]

Mechanism: Oral carbohydrate → stimulates insulin release → insulin activates Na⁺/K⁺-ATPase → K⁺ driven into cells.
This is the simplest bedside measure. A glass of sugary juice or a few sweets can help abort a mild attack.
Why this works: It exploits the same insulin-driven K⁺ uptake pathway that triggers attacks in HypoKPP/TPP (where it causes excessive intracellular K⁺ shift). In HyperKPP, this shift is therapeutic because it counteracts the K⁺ efflux.

"Mx: sugar/mild exercise" ^[2]

Mechanism: Gentle muscular activity activates the Na⁺/K⁺-ATPase in exercising muscles → K⁺ uptake into cells → lowers extracellular K⁺. Additionally, exercise-induced sympathetic activation → β₂ stimulation → further pump activation.
Practical use: At the very onset of an attack (when there is still some motor function), light movement of the limbs can abort the episode. Once frank paralysis has developed, this is obviously not possible.
Important caveat: Strenuous exercise followed by rest is a well-known trigger for HyperKPP attacks (the post-exercise K⁺ rebound). The key is mild, continuous, gentle movement — not vigorous exertion.

"Dextrose-insulin drip: 10U Actrapid IV bolus + 250mL D10 / 50mL D50 over 30–60min, repeat Q4–6h if necessary" ^[8]

Mechanism: Insulin directly stimulates Na⁺/K⁺-ATPase (via translocation of the pump to the cell surface) → drives K⁺ into cells. Dextrose is co-administered to prevent hypoglycemia.
When to use in HyperKPP: Reserved for refractory attacks where β₂-agonist and oral carbohydrate have not sufficed, or when K⁺ is > 6.0 mmol/L with ECG changes.
Expected K⁺ drop: 0.5–1.2 mmol/L within 15–60 minutes.
Monitoring: Hourly blood glucose (risk of hypo- or hyperglycemia), serial K⁺.

Why NOT to Use Dextrose Alone Without Insulin

Giving dextrose without insulin will stimulate endogenous insulin release, which is less predictable and slower. In diabetic patients, endogenous insulin may be insufficient. Always pair dextrose with exogenous insulin for reliable K⁺-lowering effect.

Already discussed above under cardioprotection. Can be repeated every 30–60 minutes if ECG changes persist.
Remember: this is membrane stabilisation, not K⁺ lowering.

"IV NaHCO₃ 8.4% 100–150mL over 30–60min: if acidotic + not fluid overload" ^[8]

Mechanism: Alkalinisation activates the Na⁺/H⁺ exchanger → H⁺ exits cells → to maintain electroneutrality, K⁺ enters cells. Also, direct stimulation of Na⁺/K⁺-ATPase.
In HyperKPP: Limited role because patients are usually NOT acidotic (the hyperkalemia is from channel dysfunction, not metabolic acidosis). Only use if concurrent acidosis is documented.
Contraindication: Fluid overload (NaHCO₃ delivers a sodium load).

Avoided Treatment	Reason
IV KCl	Obviously contraindicated — the patient is already hyperkalemic. This seems obvious but consider: a junior doctor might reflexively reach for K⁺ replacement in a patient with "periodic paralysis" without checking the K⁺ level. In HypoKPP/TPP, K⁺ replacement IS the treatment. In HyperKPP, it would worsen the attack. Always check K⁺ before treating periodic paralysis.
Ion-exchange resins (Resonium) or K⁺ binders (Patiromer, SZC)	These remove total body K⁺, which is normal in HyperKPP. They have slow onset (hours) and could cause rebound hypokalemia. Reserved for secondary hyperkalemia with true K⁺ excess. "Oral potassium binders have onset time in the hours — for long-term control" ^[15]
Dialysis	Removes K⁺ from the body, which is inappropriate when total body K⁺ is normal. Only indicated if concurrent renal failure or life-threatening arrhythmia refractory to all medical therapy.
Succinylcholine (in any perioperative setting)	Depolarising agent → massive K⁺ release from muscle → catastrophic worsening.
Cold IV fluids	Cold exposure is a trigger — avoid hypothermia in resuscitation.

4. Chronic / Prophylactic Management

The goal of long-term management is to reduce the frequency and severity of attacks and prevent the development of fixed myopathy. This requires a combination of lifestyle modification and pharmacological prophylaxis.

Precipitating factors for HyperKPP: "Stress, heavy exercise, fasting, K⁺-rich meals" ^[1]

Measure	Mechanism / Rationale
Low-K⁺ diet	Reduces dietary K⁺ load → less extracellular K⁺ accumulation post-absorption → fewer triggers. Avoid potassium-rich foods: bananas, oranges, potatoes, tomatoes, nuts, dried fruits, chocolate.
↓K⁺ intake ^[2]	Same as above — explicitly noted as prophylactic
Avoid prolonged fasting	Fasting reduces insulin → less K⁺ uptake into cells → mild hyperkalemia → triggers attack. Advise regular small meals.
Avoid cold exposure	Cold slows Na⁺/K⁺-ATPase and worsens channel inactivation defect. Dress warmly, avoid cold water immersion, pre-warm before exercise in cold weather.
Moderate exercise; avoid strenuous exercise followed by abrupt rest	Vigorous exercise → catecholamine-driven K⁺ uptake → post-exercise rebound K⁺ efflux → triggers attack. Recommend regular moderate activity with gradual cool-down.
Frequent small carbohydrate-containing meals	Maintain steady insulin levels → continuous K⁺ uptake into cells → prevents K⁺ peaks.
Avoid stress where possible	Catecholamine surge → post-stress K⁺ rebound.

Contrast with TPP/HypoKPP Lifestyle Advice

In HypoKPP and TPP, patients are told to avoid high-carbohydrate meals (because insulin-driven K⁺ shift into cells triggers attacks). In HyperKPP, the advice is the opposite — carbohydrate intake is actually therapeutic. This is a classic exam trap. The trigger-avoidance strategy is completely reversed because the K⁺ direction is opposite.

4.2 Pharmacological Prophylaxis

"Mx: sugar/mild exercise, thiazide, β₂ agonist, IV Ca (acute), ↓K⁺ intake, dichlorphenamide (prophylactic)" ^[2]

Drug: Hydrochlorothiazide 25–50 mg daily or chlorthalidone.
Mechanism: Thiazides inhibit the Na⁺/Cl⁻ co-transporter (NCC) in the distal convoluted tubule → increased Na⁺ delivery to collecting duct → enhanced K⁺ secretion via ROMK channels → mild kaliuresis (urinary K⁺ loss) → lowers baseline serum K⁺ → reduces the frequency of hyperkalemia-triggered attacks.
Why thiazides specifically: They produce a mild, sustained hypokalemic tendency — exactly what you want in a patient whose attacks are triggered by elevated K⁺. Loop diuretics (furosemide) also lower K⁺ but are more aggressive and short-acting, with a risk of volume depletion.
Side effects: Hypokalemia (actually desired here, but monitor to avoid severe hypoK < 3.0), hyponatremia, hyperuricemia, hyperglycemia, hyperlipidemia.
Monitoring: Serum electrolytes every 1–3 months initially, then 6-monthly once stable.

"Dichlorphenamide (prophylactic)" ^[2]

Drug: Dichlorphenamide 50–200 mg/day (preferred, FDA-approved for periodic paralysis) or acetazolamide 250–500 mg/day (more widely available, used off-label).
Mechanism: Carbonic anhydrase (CA) inhibitors work at multiple levels:
1. Renal: Inhibit CA in the proximal tubule → bicarbonaturia → metabolic acidosis → mild intracellular acidosis activates Ca²⁺-activated K⁺ channels in muscle → enhanced K⁺ uptake into muscle cells → lowers extracellular K⁺.
2. Skeletal muscle: Directly affects intracellular pH → modulates channel gating → reduces the persistent Na⁺ current through mutant channels (exact mechanism still debated).
3. Kaliuretic effect: Mild increase in urinary K⁺ excretion.
Evidence: Dichlorphenamide was shown to reduce attack frequency in a randomised controlled trial in HyperKPP patients (though the evidence base is small given disease rarity).
Important caveat: CA inhibitors are highly effective in HypoKPP but have a more variable response in HyperKPP — some patients improve, others worsen. The response may depend on the specific SCN4A mutation. Start at a low dose and up-titrate with close monitoring.
Side effects: Paraesthesia (tingling in fingers/toes — due to metabolic acidosis), renal calculi (alkaline urine → calcium phosphate stones), taste alteration, fatigue.
Contraindications: Sulfonamide allergy (these drugs are sulfonamide derivatives), severe hepatic or renal impairment, adrenal insufficiency.

"β₂ agonist" ^[2]

Drug: Inhaled salbutamol PRN at onset of symptoms, or in some cases regular low-dose oral β₂-agonist.
Mechanism: As discussed — activates Na⁺/K⁺-ATPase → K⁺ uptake into cells → prevents K⁺ rise.
Use: More as a rescue/PRN treatment than a standing prophylactic, though some patients find regular use reduces attack frequency.
Side effects: Tremor, tachycardia, hypokalemia if overused.

Agent	Mechanism	Notes
Mexiletine (sodium channel blocker)	Blocks the persistent Na⁺ current through mutant Nav1.4 channels → reduces membrane depolarisation → reduces both myotonia and weakness	Primarily used for myotonia in HyperKPP. Can be very effective for reducing stiffness between attacks. Dose: 200 mg TDS. Monitor ECG (risk of cardiac conduction delay — mexiletine is a class IB antiarrhythmic).
Fludrocortisone (synthetic mineralocorticoid)	Enhances renal K⁺ excretion (aldosterone effect on collecting duct ROMK/ENaC) → lowers serum K⁺	Rarely used; risk of hypertension and fluid retention.

This comparison is crucial for exams because the treatments are nearly opposite in some respects:

Treatment	HyperKPP	HypoKPP	TPP
Acute: K⁺ replacement	Contraindicated (already hyperK)	YES — oral/IV KCl	YES — but cautiously (rebound hyperK 40–59%) ^[5]
Acute: carbohydrate / insulin	Therapeutic (drives K⁺ into cells)	Contraindicated (worsens hypoK)	Contraindicated
Acute: β₂-agonist	Therapeutic	Contraindicated (worsens hypoK)	Avoid (SABA can precipitate TPP attack ^[5])
Acute: IV calcium	If ECG changes	If ECG changes	If ECG changes
Prophylaxis: thiazide	YES (promotes kaliuresis)	No (worsens hypoK)	No
Prophylaxis: acetazolamide / dichlorphenamide	Variable response	First-line prophylaxis	Not indicated (treat thyrotoxicosis)
Prophylaxis: low K⁺ diet	YES	No (need K⁺)	No
Prophylaxis: low CHO diet	No (CHO is helpful)	YES	YES — "low salt diet, appropriate carbohydrate/alcohol intake" ^[7]
Prophylaxis: propranolol	Not first-line	Not indicated	YES — "propranolol to blunt Na-K ATPase" ^[5]
Definitive treatment	None (genetic disease)	None (genetic disease)	Anti-thyroid treatment ^[5]

TPP management: "K supplement: IV KCl in NS (not D5) / oral K, note rebound hyperK. Propranolol: to blunt Na-K ATPase. Definitive anti-thyroid treatment" ^[8]

TPP prevention: "Low salt diet, appropriate carbohydrate/alcohol intake, spironolactone, propranolol" ^[7]

Critical Exam Pearl

The treatments for the three types of periodic paralysis are essentially mirror images. What helps one can harm another. The single most dangerous error is giving K⁺ to a HyperKPP patient or giving salbutamol to a HypoKPP/TPP patient. Always check the K⁺ level before treating any periodic paralysis.

6. Special Situations

"Triggers include anaesthesia" ^[2]

Principle	Detail
Avoid succinylcholine	Depolarising neuromuscular blocker → opens Na⁺ channels → massive K⁺ efflux from muscle → can precipitate life-threatening hyperkalemia and cardiac arrest. Use non-depolarising agents (rocuronium, atracurium, cisatracurium) instead.
Avoid hypothermia	Cold triggers attacks — maintain normothermia intraoperatively with warming blankets, warm IV fluids, heated humidified inspired gases.
Monitor K⁺ and ECG closely	Perioperative stress + fasting → dual triggers. Check K⁺ pre-op, intra-op, and post-op.
Avoid prolonged fasting	Give IV dextrose if the patient must be fasted pre-operatively → maintains insulin-driven K⁺ uptake.
Alert anaesthetist	Document the diagnosis prominently in the medical notes. Consider a MedicAlert bracelet.
Post-operative mobilisation	Early gentle mobilisation to avoid post-rest K⁺ rebound.

Malignant Hyperthermia Overlap

Some SCN4A mutations have been associated with a malignant hyperthermia–like reaction under anaesthesia. While the classical MH gene is RYR1, HyperKPP patients should be treated with the same precautions as MH-susceptible patients: avoid volatile halogenated agents (halothane, isoflurane, sevoflurane, desflurane) and succinylcholine. Use total intravenous anaesthesia (TIVA) with propofol and remifentanil where possible. Have dantrolene available.

HyperKPP is AD → 50% chance of transmission.
Attacks may increase or decrease during pregnancy (unpredictable).
Thiazide diuretics are relatively contraindicated in pregnancy (risk of neonatal electrolyte disturbances, placental hypoperfusion). Acetazolamide is category C — use only if benefits outweigh risks.
Genetic counselling pre-conception is recommended.
Delivery should be planned with anaesthesia team aware of the diagnosis (avoid succinylcholine for caesarean section, maintain normothermia).

Topic	Detail
Inheritance	Autosomal dominant ^[1]^[3] → 50% transmission risk per pregnancy.
Penetrance	Near-complete ^[1] → most carriers will manifest symptoms.
Predictive testing	Offer to at-risk first-degree relatives (siblings, children). Cascade screening of the family.
Prenatal testing	Available if mutation is known; ethical considerations apply.
Prognosis counselling	Attacks tend to decrease after 4th decade, but may be replaced by fixed myopathy. Life expectancy is generally normal.

Parameter	Frequency	Purpose
Serum K⁺	Every 3–6 months (stable); more frequently during medication titration	Ensure K⁺ is in low-normal range on thiazide therapy; avoid severe hypoK
ECG	Annually or if symptoms change	Screen for conduction abnormalities; baseline for perioperative reference
Serum bicarbonate	Every 3–6 months if on acetazolamide/dichlorphenamide	Monitor for excessive metabolic acidosis
Renal function and urine pH	Annually if on CA inhibitor	Screen for renal calculi (alkaline urine → calcium phosphate stones)
Muscle strength assessment	Annually	Detect early fixed myopathy (MRC grading, functional assessment)
CK	Periodically	Persistently elevated CK may indicate ongoing myofibre damage
Attack diary	Ongoing (patient-maintained)	Track frequency, triggers, severity to guide treatment adjustments

High Yield Summary — Management of HyperKPP

Acute attack:

Cardiac monitoring + ECG — always.
IV calcium gluconate if K⁺ > 6.5 or ECG changes (stabilises membrane, does NOT lower K⁺). Omit if digoxin toxicity ^[8].
Inhaled salbutamol 10–20 mg nebulised — activates Na⁺/K⁺-ATPase → shifts K⁺ into cells ^[2].
Oral carbohydrate (sugar, juice) — stimulates insulin → K⁺ uptake ^[2].
Mild exercise — activates Na⁺/K⁺-ATPase ^[2].
Insulin-dextrose drip if refractory ^[8].
Do NOT give K⁺ replacement, ion-exchange resins, dialysis, or succinylcholine.

Chronic prophylaxis:

Trigger avoidance: low-K⁺ diet, avoid fasting, cold, strenuous exercise ^[1]^[2].
Thiazide diuretics — promote renal K⁺ loss → lower baseline K⁺ ^[2].
Dichlorphenamide or acetazolamide — variable response in HyperKPP (better in HypoKPP) ^[2].
Mexiletine — for myotonia (Na⁺ channel blocker targeting the persistent current).
Genetic counselling — AD inheritance, 50% transmission, near-complete penetrance.

Anaesthesia: Avoid succinylcholine, volatile agents; maintain normothermia; use TIVA; have dantrolene available.

Key contrast with TPP: In TPP, you give K⁺ (cautiously), propranolol, and anti-thyroid treatment. In HyperKPP, K⁺ is contraindicated and carbohydrate is therapeutic — the opposite approach.

Active Recall - Management of HyperKPP

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Periodic Paralysis comparison table (p. 1652) ^[2] Senior notes: Ryan Ho Neurology.pdf — Periodic paralysis management (p. 194) ^[3] Lecture slides: Chemical Pathology Seminar_Potassium.pdf (p. 32) ^[4] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (p. 27, 29) ^[5] Senior notes: Ryan Ho Endocrine.pdf — TPP management (p. 29) ^[7] Senior notes: Block A - I am losing weight and sweating all the time_ causes of severe, weight loss; thyrotoxicosis; hypothyroidism.pdf — TPP management (p. 34–35) ^[8] Senior notes: Maksim Medicine Notes.pdf — Hyperkalemia management (p. 210); TPP (p. 95) ^[15] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf — K⁺-lowering drugs and oral binders (p. 28)

Complications of Hyperkalemic Periodic Paralysis

HyperKPP is often described as a "benign" condition because individual attacks resolve spontaneously and the disease is not directly life-threatening in most cases. However, this label is misleading — there are several important short-term and long-term complications that significantly impact quality of life and, rarely, can be dangerous. Understanding why each complication occurs requires revisiting the underlying pathophysiology of the mutant SCN4A channel and its downstream effects.

1. Acute Complications (During or Immediately After Attacks)

"Cardiac arrhythmia — may occur with [K⁺] > 6.0. Rate of rise of [K⁺] important — more tolerable with chronic hyperK⁺" ^[4]

Why this happens: During an HyperKPP attack, K⁺ leaks out of skeletal muscle through depolarised membranes and enters the extracellular compartment. Although the hyperkalemia is typically mild (5.0–6.0 mmol/L), two factors determine cardiac risk:

Absolute K⁺ level: Cardiac myocytes, like skeletal muscle, are sensitive to extracellular K⁺. As [K⁺] rises, the resting membrane potential of cardiac myocytes becomes less negative (depolarised) → inactivation of cardiac Na⁺ channels → slowed conduction → ECG changes and arrhythmias.
Rate of rise: An acute jump from 4.0 → 6.0 mmol/L over minutes is far more dangerous than a gradual chronic rise, because the heart has no time to adapt. In HyperKPP, the rise is acute (over minutes), making the arrhythmia risk higher than the absolute number might suggest ^[4].

Types of arrhythmias:

K⁺ Level	ECG / Arrhythmia	Mechanism
5.5–6.5	Peaked T waves, shortened QT	Accelerated repolarisation
6.5–7.0	Flattened P, prolonged PR, sinus bradycardia	Atrial conduction slowing, SA node suppression
7.0–8.0	Widened QRS, bundle branch blocks	Ventricular conduction slowing
> 8.0	Sine wave, VT, VF, asystole	Complete conduction failure

"ECG: peaked T, widening of QRS, loss of P, sine wave, asystole" ^[4]

Clinical reality in HyperKPP: Life-threatening arrhythmias (VT, VF, asystole) are rare because K⁺ seldom exceeds 7 mmol/L in primary HyperKPP (contrast with renal failure where K⁺ can reach 8–10 mmol/L). However, they are not impossible, especially:

In children (smaller body compartment → same absolute K⁺ efflux produces a larger concentration change)
With concurrent triggers that independently raise K⁺ (e.g., succinylcholine during anaesthesia, rhabdomyolysis)
If the patient has co-existing cardiac disease

Prevention: Cardiac monitoring during attacks; prompt treatment to drive K⁺ into cells (β₂-agonist, carbohydrate); IV calcium gluconate if ECG changes appear.

"Usually spares respiratory and bulbar muscles" ^[2]

Why respiratory muscles are usually spared:

The diaphragm and intercostal muscles have a different ion channel expression profile from limb skeletal muscle. They are under continuous, high-frequency phasic neural drive (every breath), which keeps the membrane well-polarised and resistant to depolarisation block.
They also have a higher proportion of type I (slow-twitch) fibres, which are more resistant to the effects of the SCN4A mutation.

When it can occur:

Extremely severe attacks (very rare in HyperKPP, more a concern in severe GBS or myasthenic crisis)
Attacks occurring during general anaesthesia (where respiratory drive is suppressed by anaesthetic agents, and the compensatory neural drive is absent)
Concurrent respiratory illness reducing functional reserve

Clinical significance: Even though rare, the possibility mandates monitoring respiratory function during severe attacks — pulse oximetry, respiratory rate, and bedside spirometry (FVC) if available.

Why: Attacks can occur with little or no warning, especially if triggered by sudden cold exposure or rest after exercise. The sudden onset of flaccid weakness in the lower limbs can cause the patient to collapse.

Consequences: Fractures, head injuries, soft-tissue injuries. Children are particularly vulnerable during play or sports.

Prevention: Patients should be educated to recognise prodromal symptoms (mild stiffness or "heaviness" in the limbs preceding full weakness) and immediately sit or lie down in a safe position.

Why: Sustained depolarisation during attacks causes:

Prolonged Ca²⁺ influx through voltage-gated Ca²⁺ channels (which open during depolarisation)
Reverse-mode Na⁺/Ca²⁺ exchanger activity (elevated intracellular Na⁺ from persistent Na⁺ current → exchanger pumps Ca²⁺ in)
Intracellular Ca²⁺ overload → activation of calpains (Ca²⁺-dependent proteases) → myofibre necrosis → release of myoglobin, CK, K⁺, phosphate into the bloodstream

Clinical features: Myalgia, dark (cola-coloured) urine (myoglobinuria), markedly elevated CK ( > 10× upper limit of normal), potentially acute kidney injury (myoglobin precipitates in renal tubules).

Key point: Rhabdomyolysis is uncommon in typical HyperKPP attacks (where the hyperkalemia is mild and brief) but can occur if attacks are prolonged, frequent, or severe. It is more of a concern with succinylcholine-triggered episodes during anaesthesia.

2. Chronic / Long-Term Complications

"May develop proximal myopathy after attacks subside in 4th to 6th decades" ^[2]

This is the single most important long-term complication of HyperKPP and often becomes the primary source of disability as patients age.

Why this develops (pathophysiology from first principles):

Repeated depolarisation-induced Ca²⁺ overload: Each attack subjects muscle fibres to sustained depolarisation → prolonged opening of voltage-gated Ca²⁺ channels → intracellular Ca²⁺ rises → activates degradative enzymes (calpains, phospholipases).
Cumulative myofibre damage: Over years and hundreds of attacks, the repeated cycles of Ca²⁺-mediated injury → myofibre necrosis → attempted regeneration → eventual failure of regenerative capacity → replacement by fibrous tissue and fat.
Vacuolar myopathy: Histologically, the damaged muscle shows characteristic intracellular vacuoles — these are dilated tubular (T-tubule) and sarcoplasmic reticulum (SR) structures resulting from chronic membrane instability. The vacuoles disrupt the normal excitation-contraction coupling architecture.
Progressive fibre loss: As the myofibre population diminishes, the remaining fibres cannot compensate → fixed weakness that does not recover between attacks.

Clinical features:

Gradual onset of permanent proximal weakness — difficulty rising from a chair, climbing stairs, raising arms overhead
Muscle wasting (contrast with the muscle hypertrophy that can occur earlier in life due to myotonia)
Initially intermittent ("residual weakness" after attacks doesn't fully resolve), then persistently progressive
Typically becomes clinically apparent from the 4th to 6th decades ^[2], even as episodic attacks may be decreasing in frequency
MRC grading shows fixed weakness on serial examination

Investigations:

CK: may be chronically mildly elevated
EMG: myopathic motor unit potentials (short-duration, low-amplitude, polyphasic) ± fibrillation potentials
MRI muscle: fatty infiltration and oedema in proximal muscle groups (especially paraspinal, quadriceps, hamstrings)
Muscle biopsy: vacuolar myopathy, fibre size variability, increased internal nuclei, fibrosis, fatty replacement

Why it matters clinically: This complication means HyperKPP is not truly benign — it is a disease of lifelong accumulating damage. This provides the rationale for prophylactic treatment (reducing attack frequency reduces cumulative damage) and for long-term follow-up even when attacks appear to be improving.

The Paradox of 'Improving' HyperKPP

Patients (and their parents) often report that attacks become less frequent with age and assume the disease is "getting better." In reality, the declining attack frequency may partly reflect the fact that there are fewer viable muscle fibres left to be affected. The emergence of fixed weakness as attacks wane is the signature of this transition. Clinicians must monitor for this and counsel patients accordingly.

Why: Between attacks, the persistent Na⁺ current through mutant channels keeps the membrane at a slightly depolarised state → hyperexcitable → spontaneous repetitive firing → sustained involuntary contraction (myotonia).

Consequences of chronic myotonia:

Functional impairment: Difficulty releasing grip (e.g., shaking hands, opening jars, handling tools), delayed eye opening, stiff gait initiation
Pain and cramping: Although classic myotonia is "painless," some HyperKPP patients report discomfort or cramping, especially during prolonged myotonic episodes or in cold weather
Social and occupational impact: Grip myotonia can interfere with manual work, writing, playing musical instruments, sports
Compensatory hypertrophy (early): Chronic tonic contraction can cause increased muscle bulk, particularly in calves — this can be mistaken for Duchenne muscular dystrophy pseudohypertrophy on first presentation

Why: HyperKPP begins in childhood, is unpredictable, and affects mobility. The psychosocial burden should not be underestimated.

Domain	Impact
Childhood development	Missed school during attacks, restricted physical activity, social isolation from inability to participate in sports
Adolescence	Body image concerns (myotonia, muscle hypertrophy or later wasting), anxiety about unpredictable attacks
Employment	Occupational limitations (cannot safely perform physical labour, work at heights, operate machinery — risk of sudden collapse); cold-environment work is contraindicated
Mental health	Increased rates of anxiety and depression documented in channelopathy patients; frustration with a rare, poorly understood condition; limited specialist support
Relationships	Genetic counselling burden — 50% transmission risk to offspring; family planning decisions

Treatment	Complication	Mechanism	Prevention
Thiazide diuretics (prophylaxis)	Excessive hypokalemia	Over-kaliuresis → K⁺ drops below safe range	Regular electrolyte monitoring; target low-normal K⁺ (3.5–4.0), not true hypokalemia
Thiazide diuretics	Metabolic alkalosis, hyperuricemia, hyperglycemia	Standard thiazide side effects	Monitor metabolic panel
Acetazolamide / dichlorphenamide	Renal calculi (calcium phosphate stones)	Alkalinises urine → calcium phosphate precipitation in renal collecting system	Adequate hydration; periodic renal US
Acetazolamide / dichlorphenamide	Metabolic acidosis	CA inhibition → bicarbonaturia → systemic acidosis	Monitor serum HCO₃⁻; dose adjustment
Acetazolamide	Paradoxical worsening of attacks	In some SCN4A mutations, acetazolamide can aggravate the channel defect (mechanism poorly understood — possibly related to altered intracellular pH effects on specific mutant channels)	Start low dose, monitor response; switch to dichlorphenamide or thiazide if worsening
Mexiletine	Cardiac conduction delay	Class IB antiarrhythmic — blocks cardiac Na⁺ channels → slowed conduction	Baseline and periodic ECG; avoid in pre-existing conduction disease
β₂-agonists (high dose nebulised)	Tachycardia, tremor	Systemic β₁ and β₂ stimulation at high doses	Use lowest effective dose; cardiac monitoring during acute treatment

Acetazolamide Worsening — Exam Pearl

Unlike in HypoKPP (where acetazolamide is first-line prophylaxis), acetazolamide can paradoxically worsen attacks in some HyperKPP patients. This is a well-documented but incompletely understood phenomenon. If a patient with periodic paralysis worsens on acetazolamide, consider that the diagnosis may actually be HyperKPP rather than HypoKPP, or that the specific SCN4A mutation is acetazolamide-responsive. Dichlorphenamide or thiazides are safer first-line choices for HyperKPP prophylaxis.

"Triggers include exercise, fasting, cold exposure, anaesthesia" ^[2]

Complication	Mechanism
Perioperative hyperkalemic crisis	Succinylcholine (depolarising NMBA) → mass depolarisation of skeletal muscle → massive K⁺ efflux → life-threatening hyperkalemia → cardiac arrest. Volatile anaesthetic agents may also destabilise the mutant Na⁺ channel.
Prolonged paralysis	Severe depolarisation block during anaesthesia may not resolve quickly → delayed emergence, prolonged ventilation requirement
Malignant hyperthermia–like reaction	Some SCN4A mutations confer susceptibility to a MH-like syndrome: "hyperthermia, rigidity, metabolic/respiratory acidosis, hyperK, rhabdomyolysis" ^[2]. Rigidity + hyperthermia + rhabdomyolysis + acidosis + hyperK in the OR is a medical emergency requiring immediate dantrolene.
Hypothermia-triggered attack	Cold operating theatre, cold IV fluids, exposed patient → triggers attack during or after surgery

Prevention: As discussed in the management section — avoid succinylcholine and volatile agents; use TIVA; maintain normothermia; monitor K⁺ and ECG; have dantrolene available; flag the patient prominently in medical records.

Complication	Timeframe	Frequency	Mechanism	Severity
Cardiac arrhythmias	Acute (during attack)	Uncommon (K⁺ usually mild)	Hyperkalemia → cardiac membrane depolarisation → conduction abnormalities	Potentially life-threatening if K⁺ > 7
Respiratory failure	Acute (during attack)	Very rare	Diaphragm / intercostal depolarisation block (usually spared)	Life-threatening if it occurs
Falls and trauma	Acute	Common	Sudden lower limb weakness → collapse	Variable (fractures, head injury)
Rhabdomyolysis	Acute / subacute	Uncommon	Sustained depolarisation → Ca²⁺ overload → myofibre necrosis	Can cause AKI
Progressive fixed myopathy	Chronic (4th–6th decade)	Common (most patients)	Cumulative Ca²⁺-mediated myofibre damage → vacuolar myopathy → fibrosis	Major source of long-term disability
Chronic myotonia	Chronic (lifelong)	Common	Persistent Na⁺ current → membrane hyperexcitability	Functional impairment
Psychosocial burden	Chronic (lifelong)	Universal	Unpredictable attacks, rare disease, genetic implications	Significant QoL impact
Iatrogenic (treatment side effects)	Chronic	Variable	Drug-specific (see table above)	Usually manageable
Anaesthetic complications	Perioperative	Risk with every anaesthetic exposure	Succinylcholine / volatile agents / cold / fasting	Potentially life-threatening

Aspect	Detail
Life expectancy	Generally normal — HyperKPP is not typically a life-shortening disease if anaesthetic precautions are observed and cardiac arrhythmias are monitored
Attack natural history	Frequency tends to decrease after the 4th decade
Fixed myopathy	Develops in the majority of patients by the 5th–6th decade; severity is variable
Functional outcome	Depends on the severity of fixed myopathy and success of prophylactic treatment in reducing attack burden
Genetic implications	AD inheritance with near-complete penetrance ^[1] → 50% of offspring affected; genetic counselling is essential

High Yield Summary — Complications of HyperKPP

Cardiac arrhythmias during attacks: uncommon because hyperK is usually mild (5–6 mmol/L), but rate of rise matters ^[4]. ECG monitoring during attacks is mandatory. Life-threatening arrhythmias are rare but possible if K⁺ > 7.
Progressive fixed proximal myopathy (4th–6th decade) is the most important long-term complication — caused by cumulative Ca²⁺-mediated myofibre damage from repeated attacks → vacuolar myopathy → permanent weakness ^[2]. This is the main rationale for prophylactic treatment.
Respiratory and bulbar muscles are usually spared ^[2] — respiratory failure is very rare but possible under anaesthesia.
Falls and trauma from sudden weakness onset — patient education on prodromes is important.
Rhabdomyolysis is uncommon but can cause AKI; more likely with succinylcholine-triggered episodes.
Anaesthetic complications are a major concern: avoid succinylcholine and volatile agents; maintain normothermia; have dantrolene available; monitor K⁺ and ECG ^[2].
Iatrogenic: Acetazolamide can paradoxically worsen HyperKPP (unlike HypoKPP); thiazides can cause excessive hypoK; mexiletine can slow cardiac conduction.
Psychosocial burden is significant — unpredictable attacks from childhood, rare disease, genetic counselling needs.
Prognosis: Normal life expectancy; attacks decrease with age but are replaced by fixed myopathy.

Active Recall - Complications of HyperKPP

References

High Yield Summary

Hyperkalemic Periodic Paralysis (HyperKPP) — Key Points:

Autosomal dominant channelopathy caused by SCN4A mutations (gain-of-function in skeletal muscle Na⁺ channel Nav1.4) ^[1]^[2]^[3]
Rare (~1/200,000), equal sex distribution, onset age 1–10 years, near-complete penetrance ^[1]^[2]
Precipitated by exercise, cold, fasting, K⁺-rich meals, anaesthesia ^[2]^[3]
Pathophysiology: impaired fast inactivation → persistent Na⁺ current → depolarisation block → flaccid paralysis + K⁺ efflux → mild hyperkalemia (5–6 mmol/L)
Clinical features: Episodic flaccid weakness (proximal > distal, LL > UL), spares respiratory/bulbar muscles, attacks last minutes to a few hours ^[1]^[2]^[3]
Myotonia between/early in attacks — a distinguishing feature from HypoKPP and TPP ^[2]
Late progressive proximal myopathy develops in 4th–6th decades ^[2]
Sensation intact, reflexes reduced during attacks, normal between attacks (early disease)
Cardiac arrhythmias are uncommon (mild hyperkalemia) but ECG monitoring is still warranted

High Yield Summary — Differential Diagnosis of HyperKPP

The single most important investigation to differentiate periodic paralyses is serum K⁺ during an attack: ↑ = HyperKPP (or secondary hyperK); ↓ = HypoKPP or TPP.
Myotonia distinguishes HyperKPP from HypoKPP and TPP (both lack myotonia).
TFT must always be checked to exclude TPP — especially in Hong Kong where TPP in young Asian males is far more common than primary periodic paralysis.
Normal K⁺ between attacks distinguishes primary PP from secondary hyperkalemia (renal failure, Addison's, drugs).
Age of onset helps: 1–10 y (HyperKPP) → 10–20 y (HypoKPP) → > 20 y (TPP).
GBS is the main non-myopathic mimic — distinguished by monophasic progressive course, sensory involvement, autonomic dysfunction, and CSF findings.
Always consider pseudohyperkalemia (haemolysed sample, EDTA contamination) before diagnosing true hyperkalemia.
Anaesthesia risk: HyperKPP patients — avoid succinylcholine (risk of severe hyperkalemia and sustained depolarisation).

High Yield Summary — Diagnosis of HyperKPP

No single diagnostic criterion exists — diagnosis is clinical + biochemical + genetic.
Three essential investigations during an acute attack: serum K⁺ (high), ECG (peaked T waves), TFT (normal, excludes TPP).
Serum K⁺ must be normal between attacks — persistent hyperkalemia = secondary cause (renal failure, Addison's, drugs).
Always exclude pseudohyperkalemia first: haemolysis, EDTA tube, thrombocytosis, leukocytosis ^[8]^[9]^[12].
Myotonic discharges on EMG between attacks are a key supportive finding — absent in HypoKPP and TPP.
Genetic testing (SCN4A) is the definitive confirmatory test — identifies T704M (~50%) or M1592V (~30%).
Provocative KCl loading is historical and rarely done now; genetic testing has replaced it.
ECG progression of hyperkalemia: peaked T → flat P / long PR → wide QRS → sine wave → asystole ^[4]^[8]^[12].
The long exercise test (McManis protocol) is a non-invasive electrophysiological test that can support the diagnosis between attacks.
Muscle biopsy (vacuolar myopathy) is reserved for diagnostic uncertainty.

High Yield Summary — Management of HyperKPP

Acute attack:

Cardiac monitoring + ECG — always.
IV calcium gluconate if K⁺ > 6.5 or ECG changes (stabilises membrane, does NOT lower K⁺). Omit if digoxin toxicity ^[8].
Inhaled salbutamol 10–20 mg nebulised — activates Na⁺/K⁺-ATPase → shifts K⁺ into cells ^[2].
Oral carbohydrate (sugar, juice) — stimulates insulin → K⁺ uptake ^[2].
Mild exercise — activates Na⁺/K⁺-ATPase ^[2].
Insulin-dextrose drip if refractory ^[8].
Do NOT give K⁺ replacement, ion-exchange resins, dialysis, or succinylcholine.

Chronic prophylaxis:

Trigger avoidance: low-K⁺ diet, avoid fasting, cold, strenuous exercise ^[1]^[2].
Thiazide diuretics — promote renal K⁺ loss → lower baseline K⁺ ^[2].
Dichlorphenamide or acetazolamide — variable response in HyperKPP (better in HypoKPP) ^[2].
Mexiletine — for myotonia (Na⁺ channel blocker targeting the persistent current).
Genetic counselling — AD inheritance, 50% transmission, near-complete penetrance.

Anaesthesia: Avoid succinylcholine, volatile agents; maintain normothermia; use TIVA; have dantrolene available.

Key contrast with TPP: In TPP, you give K⁺ (cautiously), propranolol, and anti-thyroid treatment. In HyperKPP, K⁺ is contraindicated and carbohydrate is therapeutic — the opposite approach.

High Yield Summary — Complications of HyperKPP

Cardiac arrhythmias during attacks: uncommon because hyperK is usually mild (5–6 mmol/L), but rate of rise matters ^[4]. ECG monitoring during attacks is mandatory. Life-threatening arrhythmias are rare but possible if K⁺ > 7.
Progressive fixed proximal myopathy (4th–6th decade) is the most important long-term complication — caused by cumulative Ca²⁺-mediated myofibre damage from repeated attacks → vacuolar myopathy → permanent weakness ^[2]. This is the main rationale for prophylactic treatment.
Respiratory and bulbar muscles are usually spared ^[2] — respiratory failure is very rare but possible under anaesthesia.
Falls and trauma from sudden weakness onset — patient education on prodromes is important.
Rhabdomyolysis is uncommon but can cause AKI; more likely with succinylcholine-triggered episodes.
Anaesthetic complications are a major concern: avoid succinylcholine and volatile agents; maintain normothermia; have dantrolene available; monitor K⁺ and ECG ^[2].
Iatrogenic: Acetazolamide can paradoxically worsen HyperKPP (unlike HypoKPP); thiazides can cause excessive hypoK; mexiletine can slow cardiac conduction.
Psychosocial burden is significant — unpredictable attacks from childhood, rare disease, genetic counselling needs.
Prognosis: Normal life expectancy; attacks decrease with age but are replaced by fixed myopathy.

Hyperkalemic Periodic Paralysis

1. Definition

2. Epidemiology

3. Anatomy and Function of the Relevant Ion Channel

3.1 The Voltage-Gated Sodium Channel (Nav1.4)

3.2 Normal Potassium Handling in Skeletal Muscle

3.3 Why the Sodium Channel Matters

4. Etiology

4.1 Genetic Basis

4.2 Precipitating Factors (Triggers)

5. Pathophysiology

5.1 Molecular Mechanism

5.2 Why Myotonia Occurs Between/Early in Attacks

5.3 Why Late-Onset Fixed Myopathy Develops

6. Classification

6.1 Within the Periodic Paralyses

6.2 Clinical Subtypes of HyperKPP

6.3 Relationship to Other SCN4A Channelopathies

7. Clinical Features

7.1 Symptoms

7.1.1 Episodic Muscle Weakness/Paralysis (The Cardinal Feature)

7.1.2 Myotonia (Muscle Stiffness)

7.1.3 Progressive Fixed Weakness (Late Feature)

7.1.4 Precipitant-Related Symptoms

7.2 Signs

7.2.1 During an Attack

7.2.2 Between Attacks

7.2.3 Cardiac Considerations

8. Important Pathophysiological Comparisons

8.1 HyperKPP vs Thyrotoxic Periodic Paralysis (TPP)

8.2 HyperKPP vs Hypokalemic Periodic Paralysis (HypoKPP)

9. Summary of Pathophysiology Flow

Active Recall - Hyperkalemic Periodic Paralysis (Overview, Pathophysiology & Clinical Features)

References

1. Framework for the Differential Diagnosis

2. Systematic Differential Diagnosis

2.1 Other Periodic Paralyses (Most Important Differentials)

2.1.1 Hypokalemic Periodic Paralysis (HypoKPP)

2.1.2 Thyrotoxic Periodic Paralysis (TPP)

2.1.3 Paramyotonia Congenita (PMC)

2.1.4 Andersen-Tawil Syndrome (ATS / Periodic Paralysis Type 3)

2.2 Secondary Causes of Hyperkalemia with Weakness

2.3 Differential Diagnosis of Generalised Quadriparesis (Non–Periodic Paralysis Causes)

2.3.1 Guillain-Barré Syndrome (GBS)

2.3.2 Myasthenia Gravis (MG)

2.3.3 Botulism

2.3.4 Transverse Myelitis / Spinal Cord Compression

2.3.5 Inflammatory Myopathies (Polymyositis/Dermatomyositis)

2.3.6 Muscular Dystrophies

2.3.7 Myotonic Dystrophy (MyD)

2.3.8 Drug-Induced Myopathy

2.3.9 Endocrine Myopathies

2.3.10 Metabolic Myopathies

2.4 Malignant Hyperthermia (MH)

3. Approach to Narrowing the Differential

4. Summary Differential Diagnosis Table

Active Recall - Differential Diagnosis of HyperKPP

1. Diagnostic Criteria

1.1 Clinical Diagnostic Criteria

1.2 Supportive (But Not Required) Features

2. Diagnostic Algorithm

3. Investigation Modalities

3.1 Bedside Investigations

3.1.1 Electrocardiogram (ECG)

3.1.2 Clinical Examination for Myotonia

3.2 Blood Investigations

3.2.1 Serum Electrolytes (Stat, During Attack)

3.2.2 Renal Function Tests (RFT)

3.2.3 Thyroid Function Tests (TFT)

3.2.4 Creatine Phosphokinase (CK/CPK)

3.2.5 Glucose and Venous Blood Gas (VBG)

3.2.6 Cortisol and ACTH (If Clinically Indicated)

3.2.7 Drug History Review

3.3 Electrophysiological Investigations

3.3.1 Electromyography (EMG)

3.3.2 Nerve Conduction Studies (NCS)

3.3.3 Exercise Test (Long Exercise Test / McManis Protocol)

3.4 Genetic Testing (Definitive Diagnostic Test)

3.5 Provocative Testing (Largely Historical, Rarely Done Now)

3.5.1 Oral KCl Loading Test